PEER REVIEWED PUBLICATIONS SUPPORTED BY CHRC

1. Verma S, Goodman SG, Tan MK, Daneault B, Lubelsky BJ, Mansour S, Lam AS, Laflamme D, Tymchak WJ, Welsh RC, Rose RC, Chettyll RM, Constance CM, Cieza T, Potter BJ, Hartleib MC, Khan R, Choi RF, Keeble W, Dery J-P, Shukla D, Chua GL, Bainey KR. Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECT-CVD) study. Int J Clin Pract 2021. In Press.

2. Patel A, Goodman SG, Tan M, Suskin N, McKelvie R, Mathew AL, Lutchmedial S, Dehghani P, Lavoie AJ, Huynh T, Lavi S, Philipp R, Khan R, Yan AT, Radhakrishnan S, Sedlak T, Brunner N, Kim HH, Cieza T, Kassam S, Fordyce CB, Heffernan M, Jedrzkiewicz S, Madan M, Ahmed S, Barry C, Dery JP, Bagai A; Canadian ACS Reflective II Investigators. Contemporary use of guideline-based higher potency P2Y12 receptor inhibitor therapy in patients with moderate-to-high risk non-ST-segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross-sectional study. Clin Cardiol 2021. In Press. 2021 May 13 online ahead of print.

3. Valle FH, Goodman SG, Tan M, Ha A, Mansour S, Welsh RC, Yan AT, Bainey KR, Rinfret S, Potter BJ, Khan R, Simkus G, Natarajan MK, Schwalm JD, Daneault B, Eisenberg MJ, Abunassar J, Har B, Gregoire J, Tanguay J-F, Overgaard CB, Dery J-P, De Larochelliere R, Paradis J-M, Madan M, Elbarouni B, So DYF, Quraishi A-U-R, Bagai A, for the CONNECT AF+PCI study investigators. Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation: Findings from the CONNECT AF+PCI study. CJC Open 2021. In Press.

4. Haghbayan H, Gale CP, Chew DP, Brieger D, Fox KA, Goodman SG, Yan AT. Clinical risk prediction models for the prognosis and management of acute coronary syndromes. Eur Heart J Qual Care Clin Outcomes 2021 May 3;7(3):222-228.

5. Lee JJ, Ha ACT, Dorian P, Verma M, Goodman SG, Friedrich JO. Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation. Am J Cardiol 2021 Feb 1;140:62-68.

6. Bethel MA, Mentz RJ, Merrill P, Buse JB, Chan JC, Goodman SG, Iqbal N, Jakuboniene N, Katona B, Lokhnygina Y, Lopes RD, Maggioni AP, Ohman P, Tankova T, Bakris GL, Hernandez AF, Holman RR. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care 2020;43(2):446-452.

7. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE Jr, Rockhold FW, Broderick S, Ferguson TB Jr, Williams DO, Harrington RA, Stone GW, Rosenberg Y; ISCHEMIA Research Group. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382(15):1395-1407.

8. Tavenier AH, Hermanides RS, Fabris E, Lapostolle F, Silvain J, Ten Berg JM, Lassen JF, Bolognese L, Cantor WJ, Cequier Á, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Ecollan P, Collet JP, Willems FF, Diallo A, Vicaut E, Hamm CW, Montalescot G, van ‘t Hof AWJ; ATLANTIC investigators. Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTICTrial. Thromb Haemost. 2020;120(1):65-74.

9. Leblanc K, Bell AD, Ezekowitz JA, Tan MK, Laflamme D, Goldin L, Habert J, Lin PJ, Saunders K, Ngui D, Ng AP, Desroches J, Goodman SG; OPTIMAL AF Investigators. Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) Programme. Int J Clin Pract. 2020 Dec;74(12):e13625.

10. Everett, CC, Fox KAA, Reynolds C, Fernandez C, Sharples LD, Stocken DD, Carruthers K, Hemingway H, Yan AT, Goodman SG, Brieger D, Chew DP, Gale CP. Evaluation of the impact of the GRACE risk score on the management and outcome of patients hospitalised with non-ST elevation acute coronary syndrome in the UK: protocol of the UKGRIS cluster-randomised registry based trial. BMJ Open 2019;9(9):e032165.

11. Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Alexander KP, Senior R, Boden WE, Stone GW, Goodman SG, Lopes RD, Lopez-Sendon J, White HD, Maggioni AP, Shaw LJ, Min, JK, Picard MH, Berman DS, Chaitman BR, Mark DB, Spertus JA, Cyr DD, Bhargava BB, Ruzyllo W, Wander GS, Chernyavskiy AM, Rosenberg YD, Maron DJ, on behalf of the ISCHEMIA Research Group. Baseline Characteristics of Participants in the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA). JAMA Cardiol 2019;4(3):273-286.

12. Berwanger O, Lopes RD, Moia DDF, Fonseca FA, Jiang L, Goodman SG, Nicholls SJ, Parkhomenko A, Averkov O, Tajer C, Malaga G, Saraiva JFK, Guimaraes HP, de Barros E Silva PGM, Damiani LP, Santos RHN, Paisani DM, Miranda TA, Valeis N, Piegas LS, Granger CB, White HD, Nicolau JC. Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial. J Am Coll Cardiol 2019;73(22):2819-2828.

13. Tan NS, Sarak B, Fox KAA, Brieger D, Steg PG, Gale CP, Bhatt DL, Spender FA, Grondin FR, Goodman SG, Yan AT, on behalf of the Canadian GRACE/GRACE-2 and CANRACE Investigators. Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure. Eur Heart J Acute Cardiovasc Care 2019;8(4):309-317.

14. Sharma A, Hagström E, Wojdyla DM, Neely ML, Harrington RA, Wallentin L, Alexander JH, Goodman SG, Lopes RD, Apixaban for Prevention of Acute Ischemic Safety Events (APPRAISE-2) Steering Committee and Investigators. Clinical Consequences of Bleeding Among Individuals with a Recent Acute Coronary Syndrome: Insights from the APPRAISE-2 Trial. Am Heart J 2019;215:106-113.

15. Lapostolle F, Van’t Hof AW, Hamm CW, Stibbe O, Ecollan P, Collet JP, Silvain J, Lassen JF, Heutz WMJM, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Ten Berg J, Zeymer U, Licour M, Tsatsaris A, Montalescot G; ATLANTIC Investigators. Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST Segment Elevation Myocardial Infarction: ATLANTIC Morphine. Am J Cardiovasc Drugs. 2019;19(2):173-18.

16. Badjatiya A, Merrill P, Buse JB, Goodman SG, Katona B, Iqbal N, Pagidipati NJ, Sattar N, Holman RR, Hernandez AF, Mentz RJ, Patel MR, Jones WS. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. Circ Cardiovasc Interv. 2019;12(12):e008018.

17. Fabris E, van’t Hof A, Hamm CW, Lapostolle F, Lassen JF, Goodman SG, ten Berg JM, Bolognese L, Cequier A, Chettibi M, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Cantor WJ, Tsatsaris W, Kerneis M, Diallo A, Vicaut E, Montalescot G, for the ATLANTIC investigators. Pre-Hospital administration of Ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial. Catheter Cardiovasc Interv 2019;93:e369-e377.

18. Fabris E, van’t Hof A, Hamm CW, Lapostolle F, Flensted Lassen J, Goodman SG, ten Berg JM, Bolognese L, Cequier A, Chettibi M, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Cantor WJ, Tsatsaris A, Kerneis M, Diallo A, Vicaut E, Montalescot G, for the ATLANTIC investigators. Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: a subanalysis of the ATLANTIC Trial. Eur Heart J Acute Cardiovasc Care 2019;8(3):208-217.

19. Berwanger O, Nicolau JC, Carvalho AC, Jiang L, Goodman S, Nicholls S, Parkhomenko A, Averkov O, Tajer C, Malaga G, Saraiva JFK, Fonseca F, Guimaraes HP, de Barros e Silva PGM, Damiani LP, Paisani DM, Lasagno CMR, Candido CT, Valeis N, Moia DDF, Piegas LS, Granger CB, White H, Lopes RD. Ticagrelor versus Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. JAMA Cardiol. 2018;3(5):391-399.

20. Ghosh-Swaby OR, Tan M, Bagai A, Yan AT, Goodman SG, Mehta SR, Fisher HN, Cohen EA, Huynh T, Cantor WJ, LeMay MR, Déry JP, Welsh RC, Udell JA. Marital Status, Living Arrangement, and Outcomes After Myocardial Infarction: Observations from the Canadian Observational Antiplatelet sTudy (COAPT). Clin Cardiol 2018;41(3):285-292.

21. Barnett AD, Cyr DD, Goodman SG, Levitan BS, Yuan Z, Hankey GJ, Singer DE, Becker RC, Breithardt G, Berkowitz SD, Halpersin JL, Hacke W, Mahaffey KW, Nessel CC, Fox KAA, Patel MR, Piccini JP. Net clinical benefit of rivaroxaban compared to warfarin in patients with atrial fibrillation: Results from ROCKET AF. Int J Cardiol 2018;257:78-83.

22. Sarak B, Goodman SG, Brieger D, Gale CP, Tan NS, Budaj A, Wong GC, Huynh T, Tan MK, Udell JA, Bagai A, Fox KAA, Yan AT, for the Global Registry of Acute Coronary Events (GRACE) Investigators and the Canadian Acute Coronary Syndromes I Investigators. Electrocardiographic findings in acute coronary syndrome patients presenting with out-of-hospital cardiac arrest. Am J Cardiol 2018;121(3):294-300.

23. Sherwood MW, Lopes RD, Sun JL, Liaw D, Harrington RA, Wallentin L, Laskowitz DT, James SK, Goodman SG, Darius H, Lewis BS, Gibson CM, Pieper KS, Alexander JH. Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. Am Heart J 2018;197:1-8.

24. Bagai A, Goodman SG, Cantor WJ, Vicaut E, Bolognese L, CequierA, Chettibi M, Hammett CJ, Huber K, Janzon M, Lapostolle F, Lassen JF, Merkely B, Storey RF, ten Berg JM, Zeymer U, Diallo A, Hamm CW, Tsatsaris A, El Khoury J, van ’t Hof AW, Montalescot G. Duration of Ischemia and Treatment Effects of Pre- Versus In-Hospital Ticagrelor in Patients with ST-Segment Elevation Myocardial Infarction: Insights from the ATLANTIC study. Am Heart J. 2018;196:56-64.

25. Worme MD, Tan MK, Armstrong DWJ, Yan AT, Tan NS, Brieger D, BudajA, Gore JM, López-Sendón J, Van de Werf F, Steg PG, Fox KAA, Goodman SG, Udell JA. Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes: Insight from the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol. 2018;122(6):944-951.

26. Hall M, Bebb OJ, Dondo T, Yan AT, Goodman SG, Bueno H, Chew DP, Brieger D, Batin PD, Farkouh M, Hemingway H, Timmis A, Fox KAA, Gale CP. Guideline-indicated treatments and diagnostics, GRACE risk score and survival for non-ST elevation myocardial infarction. Eur Heart J. 2018;39(42):3798-3806.

27. Yang A, Pon Q, Lavoie A, Crawford JJ, Harenberg S, Zimmermann RH, Booker J, Kelly S, Lavi S, Cantor WJ, Mehta SR, Bagai A, Goodman SG, Cheema AN, Dehghani P. Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI. J Thromb Thrombolysis. 2018;45(2):225-233.

28. Mentz RJ, Bethel MA, Merrill P, Lokhnygina Y, Buse JB, Chan JC, Felicio J, Goodman SG, Choi J, Gustavson SM, Iqbal N, Lopes RD, Maggioni AP, Ohman P, Pagidipati NJ, Poulter NR, Ramachandran A, Reicher B, Holman RR, Hernandez AF. Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. JAHA. 2018;7:e009304.

29. Fabris E, Van’t Hof A, Hamm CW, Lapostolle F, Lassen JF, Goodman SG, Ten Berg JM, Bolognese L, Cequier A, Chettibi M, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Cantor WJ, Rousseau H, Vicaut E, Montalescot G. Impact of presentation and transfer delays on complete ST segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. EuroIntervention 2017;13(1):69-77.

30. Venetsanos D, SederholmLawesson S, Alfredsson J, Janzon M, Cequier A, Chettibi M, Goodman SG, van‘t Hof AW, Montalescot G, Swahn E. Association between gender and short term outcome in patients with ST elevation myocardial infarction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis. BMJ Open 2017;7:e015241.

31. Bagai A, Alexander KP, Berger JS, Senior R, Sajeev C, Pracon R, Mavromatis K, Lopez-Sendón JL, Gosselin G, Diaz A, Perna G, Drozdz J, Humen D, Petrauskiene B, Cheema AN, Phaneuf D, Banerjee S, Miller TD, Kedev S, Schuchlenz H, Stone GW, Goodman SG, Mahaffey KW, Jaffe AS, Rosenberg YD, Bangalore S, Newby LK, Maron DJ, Hochman JS, Chaitman BR. Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. Am Heart J 2017;190:135-9.

32. Russo JJ, Goodman SG, Bagai A, Déry JP, Tan MK, Fisher HN, Zhang X, Emily Zhu YE, Welsh RC, Della Siega A, Kokis A, Wong BYL, Henderson M, Lutchmedial S, Lavi S, Mehta SR, Yan AT, on behalf of the COAPT investigators. Duration of dual antiplatelet therapy and associated outcomes following percutaneous coronary intervention for acute myocardial infarction: Contemporary practice insights from the Canadian Observational Antiplatelet Study (COAPT). Eur Heart J Qual Care Clin Outcomes 2017;3(4):303-11.

33. Russo JJ, Goodman SG, Cantor WJ, Ko DR, Bagai A, Tan MK, Di Mario C, Halvorsen S, Le May M, Fernandez-Avilés F, Scheller B, Armstrong PW, Borgia F, Piscione F, Sanchez PL, Yan AT. Does renal function affect the efficacy of pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A patient level meta-analysis. Am Heart J 2017;193:46-54.

34. Van Diepen S, Fuster V, Verma S, Hamza TH, Siami FS, Goodman SG, Farkouh ME. Dual antiplatelet therapy versus aspirin monotherapy in diabetics with multivessel disease undergoing CABG: FREEDOM insights. J Am Coll Cardiol 2017;69(2):119-27.

35. Gong IY, Goodman SG, Brieger D, Gale CP, Chew CP, Welsh RC, Huynh T, DeYoung JP, Baer C, Gyenes GT, Udell JA, Fox KAA, Yan AT, on behalf of the Canadian GRACE/GRACE-2 and CANRACE Investigators. GRACE risk score: sex-based validity of in-hospital mortality prediction in Canadian patients with acute coronary syndrome. Int J Cardiol 2017;244:24-29.

36. Bagai A, Wang TY, Goodman SG, Fisher HN, Welsh RC, Dery JP, Zhang X, Zhu YE, Cheema AN, Dehghani P, Kassam SA, Ducas J, Brass N, Kim HH, Fung A, Schampaert E, Quraishi AU, Mehta SR, for the Canadian Observational AntiPlatelet sTudy (COAPT) Investigators. Longitudinal Treatment Patterns with ADP Receptor Inhibitors after Myocardial Infarction: Insights from the Canadian Observational AntiPlatelet sTudy. Int J Cardiol 2017;228:459-64.

37. Sarak B, Goodman SG, Yan RT, Tan MK, Steg PG, Tan NS, Fox KAA, Udell JA, Brieger D, Welsh RC, Gale CP, Yan AT, for the Canadian Acute Coronary Syndromes I, and Global Registry of Acute Coronary Events (GRACE) Investigators. Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome. Heart 2016;102(17):1396-1402.

38. Sra S, Tan MK, Mehta SR, Fisher HN, Déry JP, Welsh RC, Eisenberg MJ, Overgaard CB, Rose BF, Della Siega AJ, Cheema AN, Wong BYL, Henderson MA, Lutchmedial S, Lavi S, Goodman SG, Yan AT, for the Canadian Observational AntiPlatelet sTudy (COAPT) Investigators. Ischemic and Bleeding Events in Patients with Myocardial Infarction Undergoing Percutaneous Coronary Intervention Who Require Oral Anticoagulation: Insights from the Canadian Observational AntiPlatelet sTudy (COAPT). Am Heart J 2016;180:82-9.

39. Déry JP, Mehta SR, Fisher HN, Zhang X, Zhu YE, Welsh RC, Lavi S, Cieza T, Henderson MA, Lutchmedial S, Della Siega AJ, Cheema AN, Wong BYL, Kokis A, Dehghani P, Goodman SG, for the Canadian Observational AntiPlatelet sTudy (COAPT) Investigators. Baseline Characteristics, Adenosine Diphosphate Receptor Inhibitor Treatment Patterns, and Outcomes of Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention in the Prospective Canadian Observational AntiPlatelet sTudy (COAPT): Study Design and In-Hospital Findings. Am Heart J 2016;181:26-34.

40. Tan NS, Goodman SG, Cantor WJ, Russo JJ, Borgundvaag B, Fitchett D, Džavík V, Tan MK, Elbarouni B, Lavi S, Bagai A, Heffernan M, Ko DT, Yan AT. Efficacy of Early Invasive Management After Fibrinolysis for ST-Segment Elevation Myocardial Infarction in Relation to Initial Troponin Status. Can J Cardiol 2016;132(10):1221.e11-1221.e18.

41. Graham JJ, Yan AT, Tan MK, Cantor WJ, DiMario C, Jolly SS, Halvorsen S, Fernandez-Aviles F, Le May MR, Scheller B, Borgia F, Piscione F, Madan M, Goodman SG. Radial versus femoral access for percutaneous coronary intervention in ST-elevation myocardial infarction patients treated with fibrinolysis: results from the randomized routine early invasive clinical trials. Cardiovas Revasc Med 2016;17(5):295-301.

42. Arbel Y, FitzGerald G, Yan AT, Tan MK, Fox KAA, Gore JM, Steg PG, Eagle KA, Brieger D, Montalescot G, Budaj A, Lopez-Sendon J, Alvezum A, Granger CB, Goodman SG. Temporal Trends in All-Cause Mortality according to Smoking Status: Insights from the Global Registry of Acute Coronary Events. Int J Cardiol 2016;218:291-97.

43. Chan WK, Goodman SG, Brieger D, Fox KAA, Gale CP, Chew DP, Udell JA, Lopez-Sendon J, Huynh T, Yan RT, Singh SM, Yan AT. Clinical Characteristics, Management, and Outcomes of Acute Coronary Syndrome in Patients With Right Bundle Branch Block on Presentation. Am J Cardiol 2016;117(5):754-9.

44. Zhang H, Goodman SG, Yan RT, Steg PG, Kornder JM, Gyenes GT, Grondin FR, Brieger D, DeYoung JP, Gallo R, Yan AT; Canadian GRACE and CANRACE Investigators. In-hospital management and outcomes of acute coronary syndromes in relation to prior history of heart failure. Eur Heart J Acute Cardiovasc Care 2016;5(3):214-22.

45. Chan WK, Goodman SG, Brieger D, Fox KAA, Gale CP, Chew DP, Udell JA, Lopez-Sendon J, Huynh T, Yan RT, Singh SM, Yan AT. Clinical Characteristics, Management, and Outcomes of Acute Coronary Syndrome in Patients With Right Bundle Branch Block on Presentation. Am J Cardiol 2016;117(5):754-9.

46. Madan M, Halvorsen S, Di Mario C, Tan M, Westerhout CM, Cantor WJ, Le May MR, Borgia F, Piscione F, Scheller B, Armstrong PW, Fernandez-Aviles F, Sanchez PL, Graham JJ, Yan AT, Goodman SG. Relationship Between Time to Invasive Assessment and Clinical Outcomes Among Patients Undergoing an Early Invasive Strategy After Fibrinolysis for ST-Elevation Myocardial Infarction: a Patient-level Analysis of the Randomized Early Routine Invasive Clinical Trials. JACC: Cardiovascular Interventions 2015;8(1):166-74.

47. Abdel-Qadir H, Yan AT, Tan M, Borgia F, Piscione F, Di Mario C, Halvorsen S, Cantor WJ, Westerhout CM, Scheller B, Le May MR, Fernandez-Aviles F, Sánchez PL, Lee DS, Goodman SG. Consistency of Benefit From An Early Invasive Strategy After Fibrinolysis: A Patient-level Meta-Analysis. Heart 2015;101:1554-61.

48. Wang JY, Goodman SG, Saltzman I, Wong GC, Huynh T, Dery JP, Leiter LA, Bhatt DL, Welsh RC, Spencer FA, Fox KAA, Yan AT, for the Global Registry of Acute Coronary Events (GRACE/GRACE-2) and Canadian Registry of Acute Coronary Events (CANRACE) Investigators. Cardiovascular Risk Factors and In-hospital Mortality in Acute Coronary Syndromes: Insights from the Canadian Global Registry of Acute Coronary Events. Can J Cardiol 2015;31(12):1455-61.

49. Chew DP, Astley CM, Luker H, Alprandi-Costa B, Hillis G, Chow CK, Quinn S, Yan AT, Gale CP, Goodman SG, Fox KAA, Brieger D. A Cluster Randomized Trial Of Objective Risk Assessment Versus Standard Care For Acute Coronary Syndromes: Rationale and Design of The Australian GRACE Risk score Intervention Study (AGRIS). Am Heart J 2015;170(5):995-1004.

50. Khan R, Lopes RD, Neely ML, Stevens SR, Harrington RA, Diaz R, Cools F, Jansky P, Montalescot G, Atar D, Lopez-Sendon J, Flather M, Liaw D, Wallentin L, Alexander JH, Goodman SG, for the Apixaban for Prevention of Acute Ischemic Safety Events (APPRAISE)-2 Steering Committee and Investigators. Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. Heart 2015;101(18):1475-84.

51. Hess CN, James S, Lopes RD, Wojdyla DM, Neely ML, Liaw D, Hagstrom E, Bhatt DL, Husted S, Goodman SG, Lewis BS, Verheugt FWA, De Caterina R, Ogawa H, Wallentin L, Alexander JH. Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: insights from the Apixaban for Prevention of Acute Ischemic Events 2 (APPRAISE-2) trial. J Am Coll Cardiol 2015; 66(7):777-87.

52. Alnasser SM, Huang W, Gore JM, Steg PG, Eagle KA, Anderson FA Jr, Fox KA, Gurfinkel E, Brieger D, Klein W, van de Werf F, Avezum A, Montalescot G, Gulba DC, Budaj A, Lopez-Sendon J, Granger CB, Kennelly BM, Goldberg RJ, Fleming E, Goodman SG, on behalf of the GRACE Investigators. Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. Am J Med 2015;128(7):766-75.

53. Russo JJ, Goodman SG, Cantor WJ, Tan MK, Borgundvaag B, Fitchett D, Džavík V, Yan RT, Graham JJ, Mehta SR, Yan AT. Efficacy and Safety of a Routine Early Invasive Strategy in Relation to Time from Symptom Onset to Fibrinolysis (A Subgroup Analysis of TRANSFER-AMI). Am J Cardiol 2015;115:1005-12.

54. Patel AD, Tan MK, Angaran P, Bell AD, Berall N, Bucci C, Demchuk AM, Essebag V, Goldin L, Green MS, Gregoire JC, Gross PL, Heilbron B, Lin PJ, Ramanathan K, Skanes A, Wheeler BH, Goodman SG. Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients from the CO-ordinated National Network to Engage physicians in the Care and Treatment of patients with Atrial Fibrillation chart audit (CONNECT AF). Am J Cardiol 2015;115: 641-646.

55. Singh SM, FitzGerald G, Yan AT, Brieger D, Fox KAA, López-Sendón J, Yan RT, Eagle KA, Steg PG, Budaj A, Goodman SG. High grade atrioventricular block in acute coronary syndromes – insights from the Global Registry of Acute Coronary Events. Eur Heart J 2015;36:976-83.

56. Rizvi SJ, Casanova A, Tan M, Lin P, McIntyre RS, Grima E, Kennedy SH. The effect of depression in the workplace and contributing factors across Canada: Results from the InSight Study. Can J Psychiatry 2014;59(7):349-57.

57. Bakal JA, Roe MT, Ohman EM, Goodman SG, Fox KAA, Zheng Y, Westerhout CM, Hochman JS, Lokhnygina Y, Brown EB, Armstrong PW. Applying novel methods to assess clinical outcomes: Insights from the TRILOGY ACS trial. Eur Heart J 2015 Feb 7;36(6):385-92a.

58. Bagai A, Tan M, Di Mario C, Halvorsen S, Cantor WJ, Le May MR, Fernandez-Aviles F, Scheller B, Armstrong PW, Borgia F, Piscione F, Sánchez PL, Westerhout CM, Goodman SG, Yan AT. Routine Invasive Management Early After Fibrinolysis: Relationship between Baseline Risk and Treatment Effects in a Pooled Patient-Level Analysis of Seven Randomized Controlled Trials. Am Heart J 2014;168(5):757-765.

59. Gandhi S, Zile B, Tan MK, Saranu J, Bucci C, Yan AT, Robertson P, Quantz MA, Letovsky E, Tanguay JF, Dery JP, Fitchett D, Madan M, Cantor WJ, Heffernan M, Natarajan MK, Wong GC, Welsh RC, Goodman SG. Increased Uptake of Guideline Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. Can J Cardiol 2014;30:1725-31.

60. Lin S, Scales DC, Dorian P, Kiss A, Common MR, Brooks SC, Goodman SG, Salciccioli JD, Morrison LJ. Targeted Temperature Management Processes and Outcomes After Out-of-Hospital Cardiac Arrest: An observational cohort study. Crit Care Med 2014 Dec;42(12):2565-74.

61. Lincoff AM, Roe M, Aylward P, Galla J, Rynkiewicz A, Guetta V, Zelizko M, Kleiman N, White H, McErlean E, Erlinge D, Laine M, Dos Santos Ferreira JM, Goodman S, Mehta S, Atar D, Suryapranata H, Jensen SE, Forster T, Fernandez-Ortiz A, Schoors D, Radke P, Belli G, Brennan D, Bell G, Krucoff M, for the PROTECTION AMI Investigators. Inhibition of delta-Protein Kinase C by Delcasertib as an Adjunct to Primary Percutaneous Coronary Intervention for Acute Anterior ST-Segment Elevation Myocardial Infarction. Results of the PROTECTION AMI Randomized Controlled Trial. Eur Heart J 2014;35(37):2516-23.

62. Mahaffey KW, Stevens SR, White HD, Nessel CC, Goodman SG, Piccini JP, Patel MR, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Califf RM, Fox KA, Breithardt G; for the ROCKET AF Investigators. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J 2014;35(4):233-41.

63. Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, Berkowitz SD, Mahaffey KW, Patel MR, Sherwood MW, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Breithardt G, Fox KAA, Califf RM, for the ROCKET AF Investigators. Factors Associated with Major Bleeding Events: Insights from the Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). J Am Coll Cardiol 2014;63(9):891-900.

64. Montalescot G, Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Stibbe O, Ecollan P, Heutz WM, Swahn E, Collet JP, Willems FF, Baradat C, Licour M, Tsatsaris A, Vicaut E, Hamm CW; the ATLANTIC Investigators. Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. N Engl J Med 2014;371:1016-27.

65. Tan NS, Goodman SG, Cantor WJ, Tan MK, Yan RT, Bagnall AJ, Mehta SR, Fitchett D, Strauss BH, Yan AT. Comparison of the Efficacy of Pharmacoinvasive Management for ST-Segment Elevation Myocardial Infarction in Smokers Versus Non-Smokers (from the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction). Am J Cardiol 2014;114(7):955-61.

66. Vora AN, Chenier M, Schulte PJ, Goodman SG, Peterson ED, Pieper K, Jolicoeur EM, Mahaffey KW, White H, Wang TY. Long Term Outcomes Associated with Hospital Acquired Thrombocytopenia Among Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. Am Heart J 2014;168:189-196.e1.

67. Zhang H, Goodman SG, Steg PG, Budaj A, Lopez-Sendon J, Dorian P, Huynh T, Mangat I, Wong GC, Spencer FA, Yan AT, on behalf of the Global Registry of Acute Coronary Events (GRACE) ECG Substudy Investigators and the Canadian ACS Registry Investigators. Clinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock. Heart 2014;100(18):1456-61.

68. Piccini JP, Garg J, Patel MR, Lokhnygina Y, Goodman SG, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Mahaffey KW, Singer DE, Califf RM, Fox KA; on behalf of the ROCKET AF Investigators. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J 2014;35(28):1873-80.

69. Alqarawi WA, Goodman SG, Yan RT, Constance C, Fung AY, Cha JY, Gosselin G, Brieger D, Fox KAA, Van de Werf F, Yan AT, for the Global Registry of Acute Coronary Events (GRACE) and Canadian Acute Coronary Syndromes I Investigators. Prognostic Implications of Prominent R Wave in V1 or V2 in Patients with Acute Coronary Syndrome. Am J Cardiol 2014;113:1962-67.

70. Grima DT, Brown ST, Kamboj L, Bainey KR, Goeree R, Oh P, Ramanathan K, Goodman SG. Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada. Clinicoecon Outcomes Res 2014;6:49-62.

71. Russo JJ, Goodman SG, Cantor WJ, Fitchett D, Heffernan M, Borgundvaag M, Ducas J, Cohen EA, Džavik V, Mehta SR, Buller CE, Yan AT, for the TRANSFER-AMI investigators. Efficacy and Safety of a Routine Early Invasive Strategy After Fibrinolysis Stratified by Glycoprotein IIb/IIIa Inhibitor Use During Percutaneous Coronary Intervention: A Pre-Specified Subgroup Analysis of the TRANSFER-AMI Randomised Controlled Trial. Heart 2014;100(11):873-80.

72. Johnston N, Bornefalk-Hermansson A, Schenck-Gustafsson L, Held C, Goodman SG, Yan AT, Bierman AS. Do clinical factors explain persistent sex disparities in the use of acute reperfusion therapy in STEMI in Sweden and Canada? Eur Heart J Acute Cardiovasc Care 2013;2(4):350-8.

73. Huynh T, Kouz S, Yan A, Danchin N, Loughlin JO, Schampaert E, Yan R, Rinfret S, Tardif JC, Eisenberg MJ, Afilalo M, Chong A, Dery JP, Nguyen M, Lauzon C, Mansour S, Ko DT, Tu JV, Goodman S. Canada Acute Coronary Syndrome Risk Score: A new risk score for early prognostication in acute coronary syndromes. Am Heart J 2013;166(1):58-63.

74. Lee D, Goodman SG, Fox KAA, DeYoung JP, Lai CC, Bhatt DL, Huynh T, Yan RT, Gallo R, Steg PG, Yan AT. Prognostic Significance of Presenting Blood Pressure in Non-ST Segment Elevation Acute Coronary Syndrome in Relation to Prior History of Hypertension. Am Heart J 2013;166:716-22.

75. Li Q, Goodman SG, Yan RT, Gore JM, Polasek P, Lai K, Baer C, Goldberg RJ, Pinter A, Ahmad K, Kornder JM, Yan AT, on behalf of the Global Registry of Acute Coronary Events and Canadian Registry of Acute Coronary Events Investigators. Pre-hospital Cardiac Arrest in Acute Coronary Syndromes: Insights from the Global Registry of Acute Coronary Events and the Canadian Registry of Acute Coronary Events. Cardiology 2013;126(1):27-34.

76. Mohareb M, Goodman SG, Yan RT, Bhatt DL, Elbarouni B, Deyoung JP, Gallo R, Kornder JM, Welsh RC, Saposnik G, Rose B, Wong GC, Grondin FR, Yan AT; on behalf of the Canadian GRACE/GRACE2/CANRACE investigators. Treatment and outcomes of non-ST elevation acute coronary syndromes in relation to burden of pre-existing vascular disease. Int J Cardiol 2013;168(3):2720-5.

77. Rose JJ, Newby LK, Broderick S, Chiswell K, Van de Werf F, Armstrong PW, Mahaffey KW, Harrington RA, Ohman EM, Giugliano RP, Goodman SG, White HD, Califf RM, Granger CB, Lopes RD. Left Bundle Branch Block in Non–ST-Segment Elevation Acute Coronary Syndromes. Incidence, Angiographic Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2013;61:1461-3.

78. Kang JS, Goodman SG, Yan RT, Lopez-Sendon J, Pesant Y, Graham JJ, Fitchett D, Wong GC, Rose BJ, Spencer FA, Yan AT, for the Canadian GRACE and CANRACE Investigators. Management and Outcomes of Non-ST Elevation Acute Coronary Syndromes in Relation to Prior Use of Anti-Anginal Therapies (From the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE]). Am J Cardiol 2013;112:51-6.

79. Leonardi S, Stebbins A, Lopes RD, Lokhnygina Y, Bhatt DL, Stone GW, Lincoff MA, Dauerman HL, Gibson CM, White HD, Parikh K, Gruberg L, Herrmann HC, McLaurin BT, Goodman SG, Harrington RA, Mahaffey KW. Quantification of Clopidogrel Effect on Enzymatic-Estimated Infarct Size Related to Percutaneous Coronary Intervention in Patients with Acute Coronary Syndromes: Insights from the CHAMPION PCI trial. Coron Artery Dis 2013;24(4):321-327.

80. Montalescot G, Flensted Lassen J, Hamm CW, Lapostolle F, Silvain J, ten Berg JM, Cantor WJ, Goodman SG, Licour M, Tsatsaris A, van’t Hof AW, for the ATLANTIC Study Group. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind ATLANTIC study. Am Heart J 2013;165(4):515-22.

81. Bakal JA, Westerhout CM, Cantor WJ, Fernandez-Avilés F, Welsh RC, Fitchett D, Goodman SG, Armstrong PW. Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: Contribution of weighting the composite endpoint. Eur Heart J 2013;34(12):903-8.

82. Gandhi S, Dorian P, Greenlaw N, Tardif JC, Gabriel Steg P, Huynh T, Wong GC, Love MP, Poirier P, Goodman SG. Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease (CLARIFY) Registry Investigators. Characteristics and Evidence-Based Management of Stable Coronary Artery Disease Patients in Canada Compared With the Rest of the World: Insights From the CLARIFY Registry. Can J Cardiol 2013;30(1):132-7.

83. Nguyen TN, Abramson BL, Galluzzi A, Tan M, Yan AT, Goodman SG, Canadian GRACE Investigators. Temporal trends and referral factors for cardiac rehabilitation post-acute coronary syndrome in Ontario: Insights from the Canadian Global Registry of Acute Coronary Events. Can J Cardiol 2013;29(12):1604-9.

84. Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW. Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization: Insights Into the Safety of Long-Term Dual Antiplatelet Therapy With Reduced-Dose Prasugrel Versus Standard-Dose Clopidogrel. Circ 2013;128(8):823-33.

85. Gyenes G, Yan AT, Tan M, Welsh RC, Fox KAA, Grondin FR, DeYoung JP, Rose BF, Gallo R, Kornder JM, Wong GC, Goodman SG, for the Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) and the Canadian Registry of Acute Coronary Events (CANRACE) Investigators. Use and Timing of Coronary Angiography and Associated In-hospital Outcomes in Canadian Non ST-Segment Elevation Myocardial Infarction Patients: Insights from the Canadian Global Registry of Acute Coronary Events. Can J Cardiol 2013;29:1429-35.

86. Bajaj RR, Goodman SG, Yan RT, Bagnall AJ, Gyenes G, Welsh RC, Eagle KA, Brieger D, Ramanathan K, Grondin FR, Yan AT. Treatment and Outcomes of Patients with Suspected Acute Coronary Syndromes in Relation to Initial Diagnostic Impressions (Insights from the Canadian GRACE and CANRACE). Am J Cardiol 2013;111:202-07.

87. Bhan V, Cantor WJ, Yan RT, Mehta SR, Morrison LJ, Heffernan M, Fitchett D, Džavík V, Ducas J, Borgundvaag B, Cohen EA, Goodman SG, Yan AT, on behalf of the TRANSFER-AMI Investigators. Efficacy of Early Invasive Management Post-Fibrinolysis in Men versus Women with ST-Elevation Myocardial Infarction: A Subgroup Analysis from TRANSFER-AMI. Am Heart J 2012;164:343-50.

88. Lavi S, Cantor WJ, Casanova A, Tan MK, Yan AT, Džavík V, Fitchett D, Cohen EA, Borgundvaag B, heffernan M, Ducas J, Goodman SG, on behalf of the TRANSFER-AMI Trial Investigators. Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction. Insights from the TRANSFER-AMI trial. Am Heart J 2012;163(2):176-181.e2.

89. Poon S, Goodman SG, Yan RT, Bugiardini R, Bierman AS, Eagle KA, Johnston N, Huynh T, Grondin FR, Schenck-Gustafsson K, Yan AT, on behalf of the Canadian Acute Coronary Syndrome Registries I and II, and the Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators. Bridging the Gender Gap: Insights from a Contemporary Analysis of Sex-Related Differences in the Treatment and Outcomes of Patients Presenting with Acute Coronary Syndromes. Am Heart J 2012;163:66-73.

90. Czarnecki A, Welsh RC, Yan RT, DeYoung JP, Gallo R, Rose B, Grondin FR, Kornder JM, Wong GC, Fox KAA, Gore JM, Goodman SG, Yan AT, on behalf of the Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators. Reperfusion Strategies and Outcomes of ST-Segment Elevation Myocardial Infarction Patients in Canada: Observations from The Global Registry Of Acute Coronary Events (GRACE). Can J Cardiol 2012;28(1):40-7.

91. Amad H, Yan AT, Yan RT, Huynh T, Gore JM, Montalescot G, DeYoung JP, Gallo R, Rose B, Steg PG, Goodman SG. The Association Between Prior Use of Aspirin and/or Warfarin and the In-Hospital Management and Outcomes in Patients Presenting with Acute Coronary Syndromes: Insights from the Global Registry of Acute Coronary Events (GRACE). Can J Cardiol 2012;28(1):48-53.

92. Elbarouni B, Banihashemi SB, Yan RT, Welsh RC, Kornder JM, Wong GC, Anderson FA, Spencer FA, Grondin FR, Goodman SG, Yan AT. Temporal Patterns of Lipid Testing and Statin Therapy in Acute Coronary Syndrome Patients: The Canadian GRACE Experience. Am J Cardiol 2012;109:1418-24.

93. Yan AT, Yan RT, Cantor WJ, Borgundvaag B, Cohen EA, Fitchett DH, Dzavik V, Ducas J, Tan M, Casanova A, Goodman SG, for the TRANSFER-AMI Investigators. Relationship Between Risk Stratification at Admission and Treatment Effects of Early Invasive Management Following Fibrinolysis: Insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Eur Heart J 2011;32(16): 1994-2002.

94. Elbarouni B, Ismaeil N, Yan RT, Fox KAA, Connelly KA, Baer C, DeYoung JP, Gallo R, Ramanathan K, Pesant Y, Leiter LA, Goodman SG, Yan AT, on behalf of the Canadian Acute Coronary Syndrome Registries I and II, and the Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators. Temporal Changes in the Management and Outcome of Canadian Diabetic Patients Hospitalized for Non ST Elevation Acute Coronary Syndrome (NSTE-ACS). Am Heart J 2011;162:347-355.

95. Edwards J, Goodman SG, Yan RT, Welsh RC, Kornder JM, De Young JP, Chauret D, Picard JP, Eagle KA, Yan AT, for the Canadian Global Registry of Acute Coronary Events (GRACE) and Canadian Registry of Acute Coronary Events (CANRACE) Investigators. Has the COMMIT Trial of Early Beta Blocker Use in Acute Coronary Syndromes Impacted on Clinical Practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2011;161:291-297.

96. Spinler SA, Gallup D, Levine GN, Ferguson JJ, Rao SV, Gallo R, Ducas J, Goodman SG, Antman E, White HD, Biasucci L, Becker RC, Col JJ, Cohen M, Harrington RA, Califf RM, Mahaffey KW. Relationship between renal function and outcomes in high-risk patients with non ST-segment elevation acute coronary syndromes: Results from SYNERGY. Int J Cardiol 2010;144:36-41.

97. Yan AT, Steg PG, FitzGerald G, Feldman LJ, Eagle KA, Gore JM, Anderson FA, Lopez-Sendon J, Gurfinkel EP, Brieger D, Goodman SG, for the GRACE Investigators. Recurrent Ischemia Across the Spectrum of Acute Coronary Syndromes: Prevalence and Prognostic Significance of (Re-)Infarction and ST-segment Changes in a Large Contemporary Registry. Int J Cardiol 2010;145(1):15-20.

98. Borgia F, Goodman SG, Halvorsen S, Cantor WJ, Piscione F, LeMay MR; Fernandez-Aviles F, Sanchez PL, Dimopoulos K, Scheller B; Armstrong PW; Di Mario C. Early Routine Percutaneous Coronary Intervention After Fibrinolysis Versus Standard Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-analysis. Eur Heart J 2010;31:2156–2169.

99. Elbarasi E, Goodman SG, Yan RT, Welsh RC, Kornder J, Wong GC, Dery JP, Anderson F, Gore JM, Fox KAA, Yan AT, on behalf of the Canadian Acute Coronary Syndrome Registries I and II (ACS 1 and ACS II) and Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators. Management patterns of non-ST segment elevation acute coronary syndromes in relation to prior coronary revascularization. Am Heart J 2010;159:40-46.

100. Spencer FA, Montalescot G, Fox KAA, Goodman SG, Granger CB, Goldberg RJ, Oliveira GBF, Anderson FA, Eagle KA, Fitzgerald G, Gore JM, and for the Global Registry of Acute Coronary Events (GRACE) Investigators. Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals. An international perspective. Eur Heart J 2010 Jun;31(11):1328-36.

101. Jerzkiewicz S, Goodman SG, Yan RT, Grondin FR, Gallo R, Welsh RC, Lai K, Huynh T, Yan AT, on behalf of the Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators. Evaluation of left ventricular ejection fraction in non-ST-segment elevation acute coronary syndromes and its relationship to treatment. Am Heart J 2010;159:605-611.

102. Fox FAA, Carruthers K, Steg PHG, Avezum A, Granger CB, Montalescot G, Goodman SG, Gore JM, Quill AL, Eagle KA, for the GRACE Investigators. Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events. Eur Heart J 2010;31(6):667-75.

103. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA, on behalf of the CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during percutaneous coronary intervention. N Engl J Med 2009;361:2330-2341.

104. Harrington RA, Stone G, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV, Montalescot G, Mahaffey KW, Kleiman N, Goodman SG, Amine M, Angiolillo D, Becker R, Chew D, French W, Leisch F, Parikh K, Skerjanec S, Bhatt DL. Platelet inhibition with cangrelor in patients undergoing PCI. Results of the CHAMPION PCI Trial. N Engl J Med 2009;361:2318-2329.

105. Linefsky JP, Lin M, Pieper KS, Reist CJ, Berdan LG, Antman EM, Goodman SG, French JK, Guneri S, Roe MT, Newby LK, Harrington RA, Ferguson JJ, Califf RM, Mahaffey KW. Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the International Trial SYNERGY). Am J Cardiol 2009;104:1330-1335.

106. Jerzkiewicz S, Goodman SG, Yan RT, Welsh RC, Kornder J, DeYoung JP, Wong GC, Rose B, Grondin FR, Gallo R, Huang W, Gore JM, Yan AT, on behalf of the Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators. Temporal trends in the use of invasive cardiac procedures for non-ST-segment elevation acute coronary syndromes according to initial risk stratification. Can J Cardiol 2009;25:e370-376.

107. Johanson P, Wallentin L, Wagner G, Fu Y, Armstrong PW, Van de Werf F, Goodman SG, Granger G. ST resolution 1 hour after fibrinolysis for prediction of myocardial infarct size – Insights from ASSENT 3. Am J Cardiol 2009;103:154-158.

108. Gibson M, Pride YB, Aylward PE, Col JJ, Goodman SG, Gulba D, Bergovec M, Kunadian V, Zorkun C, Buros JL, Murphy SA, Antman EM. Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: An ExTRACT-TIMI 25 analysis. J Thromb Thrombolysis 2009;27:11-17.

109. McDonald M, Fu Y, Zeymer U, Wagner G, Goodman SG, Ross A, Granger CB, Van de Werf F, Armstrong PW. Adverse outcomes in fibrinolytic-based facilitated PCI: Insights from the ASSENT-4 percutaneous coronary intervention electrocardiographic substudy. Eur Heart J 2008;29:871-879.

110. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FWA, Goodman SG, Corbalan R, Purdy A, Murphy SA, McCabe CH, Antman E, for the TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel–thrombolysis in myocardial infarction. Circ 2008;118:1626-1636.

111. Cantor W, Kim H, Jolly S, Moe G, Mendelsohn A, Kleinfeld A, Fitchett D. B-type natriuretic peptide and serum unbound free fatty acid levels after contemporary percutaneous coronary intervention. J Invasive Cardiol 2008;20:186-188.

112. Yan RT, Yan AT, Granger CB, Lopez-Sendon J, Brieger D, Kennelly B, Budaj A, Steg PG, Georgescu AA, Hassan Q, Goodman SG, on behalf of the Global Registry of Acute Coronary Events (GRACE) Electrocardiogram Substudy Group. Usefulness of quantitative vs qualitative ST-segment depression for risk stratification of non-ST elevation acute coronary syndromes in contemporary clinical practice. Am J Cardiol 2008;101:919-924.

113. Eagle KA, Nallamothu BK, Mehta RH, Granger CB, Steg PG, Van de Werf F, López-Sendón J, Goodman SG, Quill A, Fox KAA, for the Global Registry of Acute Coronary Events (GRACE) investigators. Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999-2006: We’re getting better but we’ve got a long way to go. Eur Heart J 2008;29(5):609-617.

114. Toma M, Fu Y, Wagner GS, Goodman SG, Granger CB, Wallentin L, Van de Werf F, Armstrong PW. Risk stratification in ST elevation myocardial infarction is enhanced by combining baseline ST deviation and subsequent ST segment resolution. Heart 2008;94:e6.

115. Fox KAA, Anderson Jr, FAA, Goodman SG, Steg PG, Pieper K, Quill A, Gore JM, for the GRACE Investigators. Time course of events in acute coronary syndromes: Implications for clinical practice from the GRACE registry. Nat Clin Pract Cardiovasc Med 2008;5:580-589.

116. Yan RT, Yan AT, Granger CB, Lopez-Sendon J, Brieger D, Kennelly B, Budaj A, Steg PG, Georgescu AA, Hassan Q, Goodman SG, on behalf of the Global Registry of Acute Coronary Events (GRACE) Electrocardiogram Substudy Group. Usefulness of quantitative versus qualitative ST-segment depression for risk stratification of non-ST elevation acute coronary syndromes in contemporary clinical practice. Am J Cardiol 2008;101:919-924.

117. Bainey KR, Fu Y, Wagner GS, Goodman SG, Ross A, Granger CB, Van de Werf F, Armstrong PW, ASSENT 4 PCI Investigators. Spontaneous reperfusion in ST-elevation myocardial infarction: Comparison of angiographic and electrocardiographic assessments. Am Heart J 2008;156:248-255.

118. Miller CD, Banerjee A, Mahaffey KW, Kontos M, Fermann G, Pollack CV, Antman EM, Aylward P, Goodman SG, Santos R, Ferguson JJ, Califf RM, Hoekstra JW. Treatment and outcomes of patients with evolving myocardial infarction: Experiences from the SYNERGY trial. Eur Heart J 2007;28(9): 1079-1084.

119. Brieger D, Van de Werf F, Avezum A, Montalescot G, Kennelly BM, Granger CB, Goodman SG, Dabbous OH, Agnelli G, for the GRACE Investigators. Interactions between heparins, glycoprotein IIb/IIIa antagonists and coronary intervention. The Global Registry of Acute Coronary Events. Am Heart J 2007;153;960-969.

120. Steg PG, Lopez-Sendon J, Lopez de Sa E, Goodman SG, Gore JM, Anderson FA, Himbert D, Allegrone J, Van de Werf F. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007;167:68-73.

121. Yan A, Yan R, Kennelly B, Anderson F, Budaj A, Lopez-Sendon J, Brieger D, Allegrone J, Steg PG, Goodman SG. Relationship of ST elevation in lead aVR with angiographic findings and outcome in non-ST elevation acute coronary syndromes. Am Heart J 2007;154:71-78.

122. Fox KAA, Steg PG, Eagle KA, Goodman SG, Anderson FA, Granger CB, Flather MD, Budaj A, Quill A, Gore JM, for the GRACE investigators. Decline in rates of death and heart failure in acute coronary syndromes. Temporal trends – 1999-2006. Global Registry of Acute Coronary Events. JAMA 2007;297:1892-1900.

123. Goldberg RJ, Spencer FA, Steg PG, Flather M, Gurfinkel EP, Kennelly BM, Goodman SG, Dedrick R, Gore JM, for the GRACE investigators. Increasing use of single and combination medical therapy in patients hospitalized for acute myocardial infarction in the 21st century: A multinational perspective. Arch Intern Med 2007;167(16):1766-1773.

124. Nguyen MC, Lim YL, Walton A, Lefkovits J, Agnelli G, Goodman SG, Budaj A, Gulba DC, Allegrone J, Brieger D, for the GRACE investigators. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: Is it safe and effective to use just one antiplatelet agent? Eur Heart J 2007;28(14):1717-1722.

125. Spencer FA, Goldberg RJ, Gore JM, Fox KAA, Avezum A, Agnelli G, Kritharides L, Anderson FA, Goodman SG, Fitzgerald G, Allegrone J, Brieger D, GRACE Investigators. Comparison of ultization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein ≥ 100 mg/dl. Am J Cardiol 2007;100:913-918.

126. Murphy SA, Antman E, Van de Werf F, Goodman SG, Mahaffey K, Menown I, Cohen M, Gibson CM. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: A meta-analysis. Eur Heart J 2007;28:2077-2086.

127. Farsang C, Athyros V, Gaw A, on behalf of the ACTFAST 2 Investigators. A multicenter, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL cholesterol levels on achieving cholesterol targets: The Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) Study. Curr Med Res Opin 2007;23(8):1945-1956.

128. Yan RT, Yan AT, Allegrone J, Lopez-Sendon J, Granger CB, Gore JM, Budaj A, Georgescu AA, Hassan Q, Luchansky J, Van de Werf F, Goodman SG. Differences between local hospital and core laboratory interpretation of the admission electrocardiogram in patients with acute coronary syndromes are associated with worse outcome. Am J Cardiol 2007;100:169-174.

129. Fox KAA, Anderson Jr FA, Dabbous OH, Steg PG, López-Sendón J, Van de Werf F, Budaj A, Gurfinkel EP, Goodman SG, Brieger D, on behalf of the GRACE Investigators. Intervention in acute coronary syndromes: Do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). Heart 2007;93:177-182.

130. Fox KAA, Dabbous DH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, Avezum A, Goodman SG, Flather MD, Anderson Jr FA, Granger, for the GRACE investigators. Prediction of the risk of death and myocardial infarction in the six months following presentation with ACS: A prospective, multinational, observational study (GRACE). Br Med J 2006;333:1091-1094.

131. Petrina M, Goodman SG, Eagle K. The twelve-lead electrocardiogram as a predictive tool of mortality after acute myocardial infarction – current status in an era of revascularization and reperfusion. Am Heart J 2006;152(1):11-18.

132. Al-Faleh H, Fu Y, Wagner G, Goodman S, Sgarboss E, Granger C, Van de Werf F, Wallentin L, Armstrong PW. Unravelling the spectrum of left bundle branch block in acute myocardial infarction: Insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. Am Heart J 2006;151:10-15.

133. Goodman SG, Steg PG, Eagle KA, Fox KAA, Lopez-Sendon J, Montalescot G, Budaj A, Kennelly BM, Gore JM, Johnson J, Granger CB, Gurfinkel EP, for the GRACE Investigators. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: Lessons from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2006;151:654-660.

134. Hackam DG, Goodman SG, Anand SS. Management of risk in peripheral artery disease: Recent therapeutic advances. Am Heart J 2005;150:35-40.

135. Levine GN, Lincoff AM, Ferguson JJ, Mahaffey KW, Goodman SG, Cannon CP, Theroux P, Fox KAA. Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. Catheter Cardiovasc Interv 2005;66:149-157.

136. Goodman SG. Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: Insights from the INTERACT trial. Am Heart J 2005;149(Suppl):S73-S80.

137. Kaul P, Newby LK, Fu Y, Mark DB, Goodman SG, Wagner GS, Harrington RA, Granger CB, Van de Werf F, Ohman EM, Armstrong PW, for the VIGOUR Group. The relationship between baseline risk and treatment decisions in non-ST elevation acute coronary syndromes: An examination of international practice patterns. Heart 2005;91:876-881.

138. Barbagelata A, Di Carli MF, Califf RM, Garg J, Birnbaum Y, Grinfield L, Gibbons RJ, Granger CB, Goodman SG, Wagner GS, Mahaffey KW. Electrocardiographic infarct size assessment after thrombolysis: Insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial. Am Heart J 2005;150:659-665.

139. Johanson P, Fu Y, Goodman SG, Dellborg M, Armstrong PW, Krucoff MW, Wallentin L, Wagner GS. A dynamic model forecasting myocardial infarct size before, during and after reperfusion therapy – An ASSENT-2 ECT/VCG substudy. Eur Heart J 2005;26:1726-1733.

140. Jackevicius CA, Alter D, Cox J, Daly P, Goodman S, Filate W, Newman A, Tu JV, for the Canadian Cardiovascular Outcomes Research Team. Acute treatment of myocardial infarction in Canada 1999-2002. Can J Cardiol 2005;21:145-152.

141. Alexander JH, Yang H, Becker RC, Kodama K, Goodman S, Dyke CK, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff AM, Burton JR, Bovill EG, Kawai C, Armstrong PW, Harrington RA, on behalf of the XaNADU-ACS Investigators. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: Results of the XaNADU-ACS trial. J Thromb Haemostasis 2005;3:439-447.

142. Van de Werf F, Gore JM, Avezum A, Gulba DC, Goodman SG, Budaj A, Brieger D, White K, Fox KAA, Eagle KA, Kennelly BM, for the GRACE Investigators. Access to catheterisation facilities in patients admitted with acute coronary syndromes: Multinational registry study. Br Med J 2005;330: 441.

143. Georgescu A, Fu Y, Yau C, Hassan Q, Luchansky J, Armstrong PW, Wagner G, Van de Werf F, Goodman SG, for the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen Trial (ASSENT-3) Investigators. Short- and Long-term outcomes of patients with electrocardiographic left ventricular hypertrophy after fibrinolysis for acute myocardial infarction. Am J Cardiol 2005;96:1050-1052.

144. Petersen JL, Mahaffey KW, Becker RC, Goodman SG, Kleiman NS, Marian AJ, Stone GW, Lansky AJ, Lincoff AM, Hazen SL, Nessel CC, Toro-Figueroa L, Tate L, Reist CJ, Cohen M, Califf RM, Ferguson JJ. Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: Design and rationale of the SYNERGy library. Am Heart J 2004;148:269-276.

145. Young W, McShane J, O’Connor T, Rewa G, Goodman SG, Jaglal SB, Cash L, Coyte PC, O’Connor T. Registered nurses’ experiences with an evidence-based home care pathway for myocardial infarction clients. Can J Cardiovasc Nursing 2004;14:24-31.

146. Taher T, Fu Y, Wagner GS, Goodman SG, Fresco C, Granger CB, Wallentin L, Van de Werf F, Verheugt F, Armstrong PW. Aborted myocardial infarction in patients with ST-segment elevation: Insights from the assessment of the safety and efficacy of a new thrombolytic regimen-3 Trial Electrocardiographic substudy. J Am Coll Cardiol 2004;44:38-43.

147. Mahaffey KW, Ferguson JJ. Exploring the role of Enoxaparin in the management of high-risk patients with non-ST elevation acute coronary syndromes: The SYNERGY Trial. Am Heart J 2004;149:S81-S90.

148. Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Avezum A, Flather MD, Granger CG, Erickson S, White K, Steg PG. Adherence to Evidence-Based Therapies After Discharge for Acute Coronary Syndromes. An Ongoing, Prospective, Observational Study. Am J Med 2004;117:73-81.

149. Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, Montalescot G, for the GRACE Investigators. Acute coronary syndromes without chest pain: an underdiagnosed and undertreated high-risk group. Insights from the Global Registry of Acute Coronary Events (GRACE). Chest 2004;126:461-469.

150. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, Budaj A, Avezum A, Flather MD, Fox KAA, for the GRACE Investigators. A validated prediction model for all forms of acute coronary syndromes. A validated prediction model for all forms of acute coronary syndromes: Estimating the risk of six-month post-discharge death in the Global Registry of Acute Coronary Events (GRACE). JAMA 2004;291:2727-2733.

151. Goldberg RJ, Currie K, Sadiq I, Brieger D, Steg PG, Goodman SG, Gore JM. Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (The Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol 2004;93:288-293.

152. Furman MI, Gore JM, Anderson FA, Budaj A, Goodman SG, Avezum A, López-Sendón J, Klein W, Mukherjee D, Eagle K, Dabbous OH, Goldberg RJ, for the GRACE Investigators. Elevated Leukocyte Count and Adverse Hospital Events in Patients with Acute Coronary Syndromes: Findings from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2004;147:42-48.

153. Budaj A, Brieger D, Steg PG, Goodman SG, Fox KAA, Avezum A, Cannon CP, Mazurek T, Flather M, Dabbous OH, Van de Werf F, for the GRACE Investigators. Global patterns of use of antithrombotic and antiplatelet therapy in patients with acute coronary events. Insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2004;146:999-1006.

154. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van de Werf F, Avezum A, Goodman SG, Flather MD, Fox KAA, for the GRACE Investigators. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med 2003;163:2345-2353.

155. Fox KAA, Goodman SG, Anderson FA, Granger CB, Moscucci M, Flather MD, Spencer F, Budaj A, Dabbous OH, Gore JM, on behalf of the GRACE investigators. From guidelines to clinical practice: The impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24: 1414-1424.

156. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM, for the ESSENCE and TIMI 11B investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003;146:33-41.

157. Tjandrawidjaja MC, Fu Y, Goodman SG, Van de Werf F, Granger CB, Armstrong PW. The impact of gender on the treatment and outcomes of patients with early reperfusion afer fibrinolysis: Insights from the ASSENT 2. Eur Heart J 2003;24:1024-1034.

158. Lockwood E, Fu Y, Wing B, Van de Werf F, Granger CB, Armstrong PW, Goodman SG, for the ASSENT-2 Investigators. Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy. Am Heart J 2003;146:640-645.

159. Armstrong PW, Wagner B, Goodman SG, Van de Werf F, Granger G, Wallentin L, Fu Y, for the ASSENT 3 Investigators. ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. Eur Heart J 2003;24:1515-1522.

160. Goldberg RJ, Steg PG, Granger CB, Jackson EA, Budaj A, Brieger D, Avezum A, Goodman SG. Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (The GRACE Registry). Am J Cardiol 2002;89(7):791-796.

161. Fu Y, Goodman S, Chang W-C, Van de Werf F, Granger CB, Armstrong PW, for the ASSENT-2 Investigators. Time to treatment influences the impact of ST segment resolution on one-year prognosis: Insights from ASSENT-2. Circ 2002;104:2653-2659.

162. Antman EM, Cohen M, McCabe C, Goodman SG, Murphy SA, Braunwald E. Enoxaparin is superior to unfractionated heparin for preventing clinical events at one year follow-up of TIMI 11B and ESSENCE. Eur Heart J 2002;23:308-314.

163. Simoons ML, Krzemiñska-Pakula M, Alonso A, Goodman SG, Kali A, Loos U, Gosset F, Louer V, Bigonzi F, for the AMI-SK Investigators. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK Study. Eur Heart J 2002;23:1282-1290.

164. Fox KAA, Goodman SG, Klein W. Brieger D, Steg PG, Dabbous O, Avezum A. Management of acute coronary syndromes. Variations in practice and outcome: Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002;23:1177-1189.

165. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan C, Lopez-Sendon J, Practice variation and missed opportunities for reperfusion in ST-segment elevation myocardial infarction - findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002;359:373-377.

166. Anderson S, Pahlm O, Bacharova L, Barbagelata A, Chaitman B, Clemmensen P, Goodman S, Heden B, Klootwijk P, Lauer M, MacFarlane P, Rautaharju P, Reddy S, Selvester R, Sgarbossa E, Underwood D, Warner R, Wagner G. Standards for the function of an academic 12-lead electrocardiographic core laboratory. J Electrocardiol 2001;34:41-47.

167. Kaul P, Fu Y, Chang WC, Harrington RA, Wagner GS, Goodman SG, Granger CB, Moliterno DJ, Van de Werf F, Califf RM, Topol EJ, Armstrong PW, for the PARAGON-A and GUSTO-IIb Investigators. Prognostic value of ST segment depression in acute coronary syndromes: Insights from PARAGON-A and GUSTO-IIb Investigators. J Am Coll Cardiol 2001;38:64-71.

168. The GRACE Investigators. GRACE (Global Registry of Acute Coronary Events): A multinational registry of patients hospitalised with acute coronary syndromes. Am Heart J 2001;141:190-199.

169. Barbash GI, Birnbaum Y, Bogaerts K, Hudson M, Lesaffre E, Fu Y, Goodman SG, Houbracken K, Munsters K, Granger CB, Pieper K, Califf RM, Topol EJ, van de Werf F. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the GUSTO I and ASSENT 2 studies. Circ 2001;103:954-960.

170. Birnbaum Y, Goodman S, Barr A, Gates KB, Barbash GI, Battler A, Barbagelata A, Clemmensen P, Sgarbossa EB, Granger CB, Califf RM, Wagner GS. Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrolment electrocardiogram. Am J Cardiol 2001;88:842-847.

171. Barbagelata A, Califf RM, Sgarbossa EB, Goodman SG, Knight D, Mark DB, Granger CB, Ohman M, Wagner G. The use of resources, quality of life and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from GUSTO-I). Am J Cardiol 2000;86:24-29.

172. Sgarbossa EB, Meyer PM, Pinski SL, Pavlovic-Surjancev B, Barbagelata A, Goodman SG, Lum AS, Underwood DA, Gates KB, Califf RM, Topol EJ, Wagner GS. Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate. Am Heart J 2000;140:385-394.

173. Fox KAA, Goodman S, Bigonzi F, Le Louer V, Cohen M, and the ESSENCE Trial Investigators. Inter-regional differences and outcome in unstable angina: analysis of the international ESSENCE trial. Eur Heart J 2000;21:1433-1439.

174. O’Brien BJ, Willan A, Blackhouse G, Goeree R, Cohen M, Goodman S. Is the use of low- molecular-weight heparin (enoxaparin) in acute coronary syndrome patients cost saving in Canada? Am Heart J 2000;139:423-429.

175. Cohen M, Stinnett S, Weatherly B, Gurfinkel EP, Fromell GJ, Goodman SG, Califf RM, Fox KAA, Lee KL, for the ESSENCE Study Group. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. Am Heart J 2000;139:962-970.

176. Sgarboss EB, Pinsky SL, Barbagelata A, Goodman SG, Natale A, Gates KB, Wagner GS. ECG subanalyses in clinical trials: An investigator’s perspective. J Electrocardiol 1999;32(Suppl):114-121.

177. Hochrein J, Fucheng S, Pieper KS, Lee KL, Gates K, Armstrong PW, Weaver WD, Goodman S, Topol EJ, Califf RM, Granger CB, Wagner GS. High T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-1 substudy). Am J Cardiol 1998;81:1078-1084.

178. Sgarbossa EB, Pinski SL, Topol EJ, Califf RM, Barbagelata A, Goodman SG, Gates KB, Granger CB, Miller DP, Underwood DA, Wagner GS, for the GUSTO-1 Investigators. Acute myocardial infarction and complete left bundle branch block at hospital admission: Clinical characteristics and outcome in the thrombolytic era. J Am Coll Cardiol 1998;31:105-110.

179. Barbagelata A, Califf RM, Sgarbossa EB, Goodman SG, Stebbins AL, Granger CB, Suarez LD, Borruel M, Gates K, Starr S, Wagner GS. Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: A GUSTO-1 substudy. J Am Coll Cardiol 1997;29:770-777.

ABSTRACTS SUPPORTED BY CHRC

1. Mavromatis, K, Goodman, SG et al. Impact Of Completeness Of Revascularization On Quality-of-life In Patients With Stable Ischemic Heart Disease: Insights From The ISCHEMIA Trial (LBCT). American College of Cardiology 70th Annual Scientific Session 2021 May.

2. Badjatiya A, Merrill P, Buse J, Goodman SG, Katona B, Iqbal N, Öhman P, Pagidipati N, Sattar N, Holman RR, Hernandez AF, Mentz RJ, Patel MR, Jones WS. Patients With Diabetes and Peripheral Arterial Disease: Results From the EXSCEL Trial. J Am Coll Cardiol 2019;73(9 Suppl 1):2040.

3. Bethel MA, Mentz RJ, Merrill P, Buse JB, Chan JC, Goodman SG, Iqbal N, Jakuboniene N, Katona BG, Lokhnygina Y, Lopes RD, Maggioni AP, Ohman PK, Poulter NR, Ramachandran A, Tankova T, Zinman B, Hernandez AF, Holman RR. Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes. 2018;67(Supplement 1):522-P.

4. Patel A, Goodman SG, Tan M, Madan M, Dery JP, Yan AT, Lutchmedial S, Dehghani P, Suskin N, Khan R, Jedrzkiewicz S, McKelvie R, Barry C, Fordyce C, Brunner N, Kim HH, Huynh Y, Lavi S, Philipp R, Lavoie A, Bagai A. Contemporary Antiplatelet Therapy in Moderate to High-Risk Patients with Non-St-Segment Elevation Myocardial Infarction: Insights from fhe Canadian ACS Reflective II Study. Can J Cardiol. 2018;34(10S1):S11-12.

5. Bell A, Ezekowitz J, Tan M, Laflamme D, Goldin L, Leblanc K, Habert J, Lin P, Saunders K, Ngui D, Ng A, Desroches J, Goodman SG. Non-Vitamin K Antagonist Oral Anticoagulant (NOAC) Use and Dosing in Canadian Practice: Insights from the Optimizing Pharmacotherapy in the Management Approach to Lowering Risk in Atrial Fibrillation (OPTIMAL-AF) Program. Can J Cardiol. 2018;34(10S1):S185.

6. Bagai A, Tan M, Ha A, Mansour S, Welsh R, Bainey K, Rinfret S, Potter B, Khan R, Natarajan M, Schwalm J, Daneault B, Eisenberg M, Abunassar J, Har B, Gregoire J, Tanguay JF, Overgaard C, Dery JP, De Larochelière R, Madan M, Elbarouni B, So D, Goodman SG. Contemporary Use Of Oral Antithrombotic Therapy In Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Insights From The CONNECT AF+PCI Study. Can J Cardiol. 2018;34(10S1):S16.

7. Kerneis M, Bagai A, Huber K, Silvain J, Hamm CW, Lapostolle F, Lassen JF, Tsatsaris A, Diallo A, Vicaut E, Cantor WJ, Goodman SG, Van’t Hof AW, Montalescot G, on behalf of ACTION Group. How important is the anticoagulant strategy in primary percutaneous coronary intervention? Insights from the ATLANTIC Study. Eur Heart J 2017;38(suppl 1):1261.

8. Bianco M, Cerrato E, Bagai A, De Luca L, Biscaglia S, D’Ascenzo F, Luciano A, Destefanis P, Tomassini F, Quiros A, Chinaglia A, Goodman SG, Pozzi R, Campo G, Varbella F. In-hospital switch of P2Y12 drugs in patients presenting with acute coronary syndrome: a meta-analysis of 14 observational and randomized studies including 10961 patients. Eur Heart J 2017;38(Suppl 1):612.

9. Cerrato E, Bianco M, Bagai A, De Luca L, Biscaglia S, D’Ascenzo F, Luciano A, Destefanis P, Tizzani E, Quadri G, Tomassini F, Quiros A, Chinaglia A, Goodman SG, Gaita F, Pozzi R, Campo G, Varbella F. In-hospital switch of P2Y12 drugs in patients presenting with acute coronary syndrome: a meta-analysis of 14 observational and randomized studies including 10961 patients. Eur Heart J 2017;38(Suppl):612.

10. Piccini J, Goodman S, Levitan B, Yuan Z, Hankey GJ, Singer DE, Becker R, Breithardt G, Berkowitz S, Halperin J, Nessel C, Hacke W, Mahaffey KW, Fox KAA, Patel MR. Net clinical benefit of rivaroxaban compared with warfarin in patients with atrial fibrillation. Eur Heart J 2016;37(Suppl 1):500.

11. Worme MD, Armstrong DW, Tan MK, Yan AT, Tan NS, Brieger D, Budaj A, Gore JM, Van de Werf F, Lopez-Sendon J, Steg PG, Fox KA, Goodman SG, Udell JA. New Onset Atrial Fibrillation in Acute Coronary Syndrome: Findings from the GRACE ECG. Can J Cardiol 2016;32(Suppl 1):S164.

12. Worme MD, Tan MK, Yan AT, Tan NS, Brieger D, Budaj D, Gore JM, Van De Werf F, Lopez-Sendon J, Steg PG, Fox KAA, Armstrong DWJ, Goodman SG, Udell JA. Risk of new onset atrial fibrillation following an acute coronary syndrome: data from the GRACE registry. Eur Heart J 2016;37(Suppl 1):616.

13. Russo JJ, Goodman SG, Cantor WJ, Ko DT, Bagai A, Tan MK, Di Mario C, Halvorsen S, Le May M, Fernandez-Avilés F, Scheller B, Armstrong PW, Borgia F, Piscione F, Sanchez PL, Yan AT. Does Renal Function Affect the Efficacy of Pharmacoinvasive Strategy in Patients with ST-Elevation Myocardial Infarction? A Patient Level Meta-Analysis. Can J Cardiol 2016;32(Suppl 1):S68.

14. Ghosh-Swaby OR, Tan MK, Bagai A, Yan AT, Mehta ST, Fisher HN, Cohen DA, Huynh T, Cantor WJ, LeMay MR, Dery JP, Welsh RC, Goodman SG, Udell JA. Marital Status, Living Arrangement and Outcomes Following Myocardial Infarction: Observations from the Canadian Observational Antiplatelet Study (COAPT). Can J Cardiol 2016;32(Suppl 1):S220.

15. Dehghani P, Tan M, Mehta ST, Fisher HN, Cantor WJ, Cheema AN, Dery JP, Welsh RC, Lavi S, Kokis A, Cieza T, Ducas J, Kassam SA, Brass N, Kim HH, Fung A, Wang T, Bagai A, Goodman SG. Clopidogrel Versus Novel P2Y12 Inhibitor Use In Fibrinolysis Treated ST Segment Elevation Myocardial Infarction: Insights from the Canadian Observational Antiplatelet Study (COAPT). Can J Cardiol 2016;32(Suppl 1):S116.

16. Tan NS, Sarak B, Fox KA, Brieger D, Steg PG, Gale CP, Bhatt DL, Spencer FA, Grondin F, Wong GC, Goodman SG, Yan AT. Pulse Pressure in Acute Coronary Syndromes: Comparative Prognostic Significance with Systolic Blood Pressure. Can J Cardiol 2016;32(Suppl 1):S203.

17. Gong I, Goodman SG, Brieger D, Gale CP, Welsh RC, Huynh T, DeYoung JP, Baer C, Gyenes GT, Udell JA, Fox KA, Yan AT. GRACE Risk Score: Sex-Based Validity Of In-Hospital Mortality Prediction In Canadian Patients With Acute Coronary Syndrome. Can J Cardiol 2016;32(Suppl 1):S67.

18. Bagai A, Mehta SR, Fisher HN, Welsh RC, Dery JP, Zhang X, Zhu YE, Cheema A, Lavi S, Dehghani P, Kassam SA, Ducas J, Wang T, Brass N, Kim HH, Goodman . Switching and Premature Discontinuation of ADP Receptor Inhibitor Therapy Prescribed at Hospital Discharge Among Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From The Canadian Observational Antiplatelet Study (COAPT). Can J Cardiol 2015;31(Suppl 10):S4–S5.

19. Dery JP, Fisher HN, Zhang X, Zhu YE, Welsh RC, Mehta SR, Bagai A, Lavi S, Cieza T, Henderson MA, Lutchmedial S, Della Siega AJ, Cheema AN, Wong BY, Kokis A, Goodman SG. ADP Receptor Inhibitor Use and Switching in Patients with Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From The Canadian Observational Antiplatelet Study (COAPT). Can J Cardiol 2015;31(Suppl 10):S6.

20. Dery JP, Fisher HN, Zhang X, Zhu YE, Welsh RC, Lavi S, Quraishi A, Cohen EA, Huynh T, Cantor WJ, Le May MR, Eisenberg MJ, Rose BF, Overgaard CB, Mehta SR, Goodman SG. In-Hospital and Long-Term Ischemic and Bleeding Events in Patients with Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Final Results From The Canadian Observational Antiplatelet Study (COAPT). Can J Cardio 2015;31(Suppl 10):S7–S8.

21. Sra S, Goodman SG, Lavi S, Dery JP, Tan MK, Fisher HN, Zhang X, Zhu YE, Welsh RC, Kokis A, Dehghani, Cieza T, Fung A, Schampaert E, Mehta SR, Yan AT. Ischemic and Bleeding Events in Canadian Patients with Myocardial Infarction Undergoing Percutaneous Coronary Intervention Who Require Oral Anticoagulation: Insights from the Canadian Observational Antiplatelet Study (COAPT). Can J Cardiol 2015;31(Suppl 10):S286.

22. Russo JJ, Goodman SG, Bagai A, Dery JP, Tan MK, Fisher HN, Zhang X, Zhu YE, Welsh RC, Della Siega A, Wong BY, Henderson H, Lutchmedial S, Mehta SR, Yan AT. Duration of Dual Antiplatelet Therapy and Associated Outcomes Following Percutaneous Coronary Intervention for Acute Myocardial Infarction: Contemporary Practice Insights from the Canadian Observational Antiplatelet Study (COAPT). Can J Cardiol 2015;31(Suppl 10):S283–S284.

23. Tan NS, Goodman SG, Cantor WJ, Russo JJ, Borgundvaag B, Fitchett D, Džavík D, Tan MD, Elbarouni B, Lavi S, Bagai A, Heffernan M, Ko D, Yan AT. Efficacy of Early Invasive Management Post-Fibrinolysis for ST-Segment Elevation Myocardial Infarction in Relation to Initial Troponin Status. Can J Cardiol 2015;31(Suppl 10):S98.

24. Chan WK, Goodman SG, Brieger D, Fox KA, Gale CP, Chew DP, Udell JA, Lopez-Sendon J, Huynh T, Yan RT, Singh SM, Yan AY. Clinical Characteristics, Management and Outcomes of Acute Coronary Syndromes in Relation to Right Bundles Branch Block on Presentation. Can J Cardiol 2015;31(Suppl 10):S97.

25. Sarak B, Goodman SG, Yan RT, Tan MK, Steg PG, Tan NS, Fox KA, Udell JA, Brieger D, Kornder JM, Welsh RC, Yan AT. Prognostic Value of T-Wave Inversion on the Presenting Versus Follow-up ECG in Non-ST Elevation Acute Coronary Syndromes. Can J Cardiol 2015;31(Suppl 10):S284–S285.

26. Sherwood MW, Lopes RD, Sun JL, Harrington RA, Wallentin L, Laskowitz D, James S, Goodman SG, Darius H, Lewis BS, Liaw D, Gibson CM, Alexander JH. Apixaban Following Acute Coronary Syndromes Among Patients with Prior Stroke: Insights from the APPRAISE-2 Trial. J Am Coll Cardiol 2015;65(10S):A195.

27. Lin S, Scales DC, Dorian P, Kiss A, Common MR, Brooks SC, Goodman SG, Salciccioli JD, Morrison LJ. Targeted Temperature Management: Exploring the Association Between Processes of Care and Outcomes After Out‐of‐Hospital Cardiac Arrest. CJEM 2014;15(Suppl 1):S43.

28. Bagai A, Chaitman BR, Gosselin G, Shah BN, Diaz A, Humen D, Banerjee S, Perna GP, Schuchlenz H, Cheema AN, Wu Y, Kronenberg MV, Aronow MD, Miller TD, El-Hajjar M, Druz R, Pracon R, Newby LK, Alexander K, Goodman S, Bangalore S, Maron DJ, Hochman JS, Mahaffey KW. Substantial Variability Between Laboratories in Troponin Decision Level for Diagnosis of Myocardial Infarction and Assay 99th Percentile: Findings from the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial. J Am Coll Cardiol 2014;63(12):A466.

29. Hess CN, James S, Wojdyla DM, Lopes RD, Liaw D, Hagstrom E, Bhatt DL, Husted S, Goodman SG, Lewis BS, Verheugt FWA, De Caterina R, Ogawa H, Wallentin L, Alexander JH. Apixaban Plus Mono versus Dual Antiplatelet Therapy After Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial. Circ 2014;130(Suppl 2):A14643.

30. Lopes RD, Neely B, Ohman EM, Ardissino D, Hamm C, Goodman SG, Bhatt DL, Brown EB, White HD, Prabhakaran D, Martinez F, Nicolau JC, Fox KAA, Armstrong PW, Roe MT. Timing, Profile, and Predictors of Spontaneous Myocardial Infarction Following a Non-ST-Segment Elevation Acute Coronary Syndrome Event: Insights From the TRILOGY-ACS Trial. Circ 2013;128:A14972.

31. Lin S, Scales DC, Dorian P, Kiss A, Common MR, Brooks SC, Goodman SG, Morrison LJ. Targeted Temperature Management: Exploring the Association Between Processes of Care and Outcomes After Out-of-Hospital Cardiac Arrest. Circ 2013;128:A230.

32. Nicolau J, Bhatt D, Roe M, Neely B, Corbalan R, Leiva-Pons J, Martinez F, Goodman SG, Brown E, Verheugt F, Armstrong PW, White H, Fox KAA, Prabhakaran D, Ohman EM. The Association Between Concomitant Proton-Pump Inhibitor Use and Clinical Outcomes in Patients with Acute Coronary Syndromes Treated with Prasugrel vs. Clopidogrel and Managed without Revascularization: Insights from the TRILOGY ACS Study. J Am Coll Cardiol 2013;61(10):A39.

33. Piccini JP, Garg J, Patel MR, Lokhnygina Y, Goodman SG, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Mahaffey KW, Singer DE, Califf RM, Fox KAA. Management of Major Bleeding Events in Patients Treated With Rivaroxaban Versus Warfarin: Results From the ROCKET AF Trial. Circ 2013;128:A15879.

34. Alqarawi WA, Goodman SG, Yan RT, Constance C, Fung AY, Cha JY, Gosselin G, Brieger D, Fox KA, Van de Werf F, Yan AT. Prognostic Implications of Prominent R Waves in V1 or V2 in Patients with Acute Coronary Syndrome. Can J Cardiol 2013;29(10S):S341.

35. Bainey KR, Grima DT, Brown ST, Kamboj L, Goeree R, Oh P, Ramanathan K, Goodman SG. Economic Evaluation of Ticagrelor Versus Clopidogrel in Canadian Patients with Acute Coronary Syndromes Based on the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Can J Cardiol 2013;29(10S):S299.

36. Zhang H, Goodman SG, Steg PG, Budaj A, Lopez-Sendon J, Dorian P, Huynh T, Mangat I, Wong GC, Spencer FA, Yan AT. Clinical Significance of Left Anterior Hemiblock in Acute Coronary Syndromes. Can J Cardiol 2013;29(10S):S295.

37. Patel A, Tan MK, Angaran P, Bell AD, Berall M, Bucci C, Demchuk AM, Essebag V, Goldin L, Green MS, Gregoire JC, Gross PS, Heilbron B, Lin PF, Ramanathan K, Skanes A, Wheeler BH, Goodman SG. Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients:Insights from The Co-Ordinated National Network to Engage Physicians in the Care and Treatment of Patients with Atrial Fibrillation (CONNECT AF). Can J Cardiol 2013;29(10S):S275.

38. Gandhi S, Zile B, Tan MK, Saranu J, Bucci C, Yan AT, Robertson P, Quantz MA, Letovsky E, Tanguay J, Dery JP, Fitchett D, Madan M, Cantor WJ, Heffernan M, Natarajan MK, Wong GC, Welsh RC, Goodman SG. Underutilization of Newer Guideline-Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome (ACS) Reflective. Can J Cardiol 2013;29(10S):S265.

39. Russo JJ, Goodman SG, Cantor WJ, Fitchett D, Heffernan M, Borgundvaag B, Ducas J, Cohen EA, D_zavík V, Mehta SR, Buller CE, Yan AT. Efficacy and Safety of a Routine Pharmacoinvasive Strategy After Fibrinolysis Stratified by Glycoprotein Iib/Iiia Inhibitor Use: A Pre-Specified Subgroup Analysis of the TRANSFER-AMI Trial. Can J Cardiol 2013:29(10S):S238.

40. Dery JP, Mehta SR, Fisher H, Welsh RC, Zhu YE, Della Siega A, Cheema A, Henderson M, Lutchmedial S, Dehghani P, Lavi S, Wong BY, Kokis A, Cieza T, Kassam SA, Brass N, Goodman SG. Dual Antiplatelet Patterns in Patients with Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights from the Prospective Canadian Observational Antiplatelet Study (COAPT). Can J Cardiol 2013;29(10S):S237.

41. Nguyen T, Abramson BL, Galluzzi A, Tan M, Yan AT, Goodman SG, for the Canadian GRACE Investigators. Temporal Trends and Factors Associated with Referral for Cardiac Rehabilitation Post-Acute Coronary Syndrome: Insights from the Canadian Global Registry of Acute Coronary Events (GRACE). Circ Cardiovasc Qual Outcomes 2012;5:A255.

42. Bajaj R, Goodman SG, Yan RT, Bagnall AJ, Gyenes G, Welsh RC, Eagle KA, Brieger D, Ramanathan K, Grondin FR, Yan AT. Real-World Management and Outcomes of Patients with Suspected Acute Coronary Syndromes in Relation to Initial Diagnostic Impressions: Insights from the Canadian GRACE and CANRACE Studies. Can J Cardiol 2012;28(5S):S196.

43. Nguyen T, Abramson BL, Galluzzi A, Tan M, Yan AT, Goodman SG, for the Canadian GRACE Investigators. Temporal Trends and Factors Associated with Referral for Cardiac Rehabilitation Post-Acute Coronary Syndrome: Insights from the Canadian Global Registry of Acute Coronary Events (GRACE). Can J Cardiol 2012;28(5S):S247.

44. Li Q, Goodman SG, Polasek P, Lai K, Baer C, Gore JM, Goldberg RJ, Yan RT, Pinter A, Ahmad K, Kornder JM, Yan AT. Cardiac Arrest in Acute Coronary Syndromes: Insights from the Canadian Global Registry of Acute Coronary Events. Can J Cardiol 2012;28(5S):S134.

45. Goodman SG, Cantor WJ, Borgundvaag B, Fitchett D, Dzavik V, Ducas J, Heffernan M, Cohen EA, Yan AT, Lavi S, for the TRANSFER AMI Investigators. Enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of ST elevation myocardial infarction - Insights from the TRANSFER AMI Trial. J Am Coll Cardiol 2011;57(14):E987.

46. Gyenes G, Yan AT, Tan M, Welsh RC, Fox KA, Grondin FR, DeYoung JP, Rose BF, Casanova A, Gallo R, Kornder JM, Wong GC, Goodman SG. Is Waiting for a Coronary Angiogram on the Weekend Safe for Non-ST-segment Elevation Myocardial Infarction (NSTEMI) Patients? Insights from the Canadian Global Registry of Acute Coronary Events. Can J Cardiol 2011;27(5S):S147-148.

47. Yan AT, Yan RT, Mehta SR, Morrison LJ, Cantor WJ, Heffernan M, Fitchett D, Dzavik V, Ducas J, Lazzam C, Borgundvaag B, Cohen EA, Goodman SG. Efficacy of Early Invasive Management Post-Fibrinolysis in Men Versus Women With ST-Elevation Myocardial Infarction: A Subgroup Analysis from TRANSFER-AMI. Can J Cardiol 2011;27(5S):S152-153.

48. Goodman SG, Huang W, Gore JM, Steg PG, Eagle KA, Anderson FA, Fox KAA. The late consequences of acute coronary syndromes: 2-year follow-up outcomes, procedures, and treatment of patients from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2011;32(suppl 1):677.

49. Huynh T, Kouz S, Yan AT, Yan RT, Chong A, Schampaert E, Dery JP, Lauzon C, Afilalo M, Tardif JC, Eisenberg MJ, O'Loughlin J, Tu JV, Goodman SG. The C-AMI: A novel risk score for stratification of paitents with acute myocardial infarction. Circ 2010;122(suppl 21):A19485.

50. Yan AT, Cantor WJ, Yan RT, Borgundvaag B, Cohen EA, Dzavik V, Ducas J, Tan M, Casanova A, Goodman SG. Risk stratification at admission to identify ST-segment elevation myocardial infarction patients receiving fibrinolysis who may benefit from early angioplasty: Insights from the Trial of Routine angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Circ 2010;122(suppl 21):A15640.

51. Banihashemi B, Goodman SG, Yan RT, Welsh RC, Kornder JM, Wong GC, Anderson Jr FA, Spencer FA, Grondin FR, Yan AT. In-hospital lipid testing and statin therapy in Canadian acute coronary syndrome patients in the Global Registry of Acute Coronary Events: Increasing over time but still underused. Can J Cardiol 2010;26(Suppl D):31D.

52. Yan AT, Cantor WJ, Yan RT, Borgundvaag B, Cohen EA, Dzavik V, Ducas J, Tan M, Casanova A, Goodman SG. Risk stratification at admission to identify ST-segment elevation myocardial infarction patients receiving fibrinolysis who may benefit from early angioplasty: Insights from the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Can J Cardiol 2010;26(Suppl D):77D.

53. Yan AT, Elmanfud O, Yan RT, Elbarouni B, Wong GC, Kornder JM, Rose BF, Welsh RC, Goodman SG. Temporal trend of in-hospital major bleeding in Canadian patients with non-ST elevation acute coronary syndromes. Can J Cardiol 2009;25(Suppl B):140B.

54. Sibbald M, Yan AT, Huang W, Fox KA, Gore JM, Steg PG, Eagle KA, Brieger D, Montalescot G, Goodman SG. Association between smoking and the effectiveness and safety of early clopidogrel use in acute coronary syndrome (ACS) patients: Insights from the Global Registry of Acute Coronary Events (GRACE). Can J Cardiol 2009;25(Suppl B):139B.

55. Ismaeil NH, Goodman SG, Yan RT, DeYoung JP, Gallo R, Baer C, Ramanathan K, Yan AT. Temporal changes in the management and outcome of Canadian diabetic patients hospitalized for acute coronary syndrome (ACS). Can J Cardiol 2009;25(Suppl B):133B.

56. Welsh RC, Yan AT, Yan RT, Gallo R, Rose BF, Wong GC, Kornder JM, Grondin FR, DeYoung JP, Mehta SR, Goodman SG. Impact of prior CABG on reperfusion therapy in Canadian ST-elevation myocardial infarction (STEMI) patients: Insights from the Global Registry of Acute Coronary Events (GRACE). Can J Cardiol 2009;25(Suppl B):132B.

57. Lee TC, Goodman SG, Yan RT, Grondin FR, Welsh RC, Rose B, Gyenes G, Zimmerman RH, Brossoit R, Saposnik G, Yan AT. Disparities in management patterns and outcomes of non-ST elevation acute coronary syndrome patients with and without prior history of cerebrovascular disease. Can J Cardiol 2009;25(Suppl B):116B.

58. Edwards J, Goodman SG, Yan RT, DeYoung JP, Kornder JM, Welsh RC, Chauret D, Picard JP, Yan AT. Has the COMMIT Trial of early beta blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE). Can J Cardiol 2009;25(Suppl B):44B.

59. Gore JM, Marre M, Steg G, Brieger D, Quill A, Goodman SG, for the GRACE Investigators. Treatment and outcome of diabetic patients with an acute coronary syndrome: Has there been any improvement over time? The GRACE Registry. J Am Coll Cardiol 2008;51(10, Suppl. A):A244.

60. Banihashemi B, Goodman SG, Yan RT, Fox KA, Wong GC, De Young P, Gallo R, Grandin FR, Welsh RC, Kornder JM, Gore J, Rose B, Yan AT, on behalf of GRACE, GRACE2 Registry Investigators. Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndrome patients: The Canadian GRACE experience. Can J Cardiol 2008;24(Suppl. E):325E.

61. Yan AT, Yan RT, Welsh RC, Gore J, Wong GC, Fox KA, De Young P, Grondin FR, Gallo R, Kornder JM, Rose B, Goodman SG, on behalf of the Canadian GRACE, GRACE2 Investigators. Clopidogrel use in Canadian acute coronary syndrome patients in the Global Registry of Acute Coronary Events: Increasing over time but still underutilized. Can J Cardiol 2008;24(Suppl. E):327E.

62. Yan RT, Goodman SG, Kornder JM, Gore J, Fox KA, Grondin FR, Wong GC, De Young P, Gallo R, Welsh RC, Rose B, Yan AT, on behalf of GRACE, GRACE 2 Investigators. Prior revascularization is associated with the use of an invasive strategy in non-ST-segment elevation acute coronary syndromes in Canada: Insights from GRACE. Can J Cardiol 2008;24(Suppl E):260E.

63. Yan RT, Yan AT, Mahaffey KW, White HD, Pepine CJ, Biasucci LM, Gulba DC, Lopez-Sendon J, Goodman SG, on behalf of the SYNERGY Investigators. Prognostic significance of evolving ST-segment depression on admission and early repeat electrocardiograms in non-ST-elevation acute coronary syndromes: Insights from The SYNERGY Trial. Can J Cardiol 2008;24(Suppl E):259E.

64. Welsh RC, Yan AT, Yan RT, De Young P, Rose B, Gallo R, Grondin FR, Kornder JM, Gore J, Wong GC, Fox KA, Goodman SG, on behalf of the GRACE, GRACE2 Investigators. Reperfusion strategies and the role of percutaneous coronary intervention in Canadian ST-segment elevation myocardial infarction patients: Observations from GRACE/GRACE2. Can J Cardiol 2008;24(Suppl E):67E.

65. Wong JA, Goodman SG, Yan RT, Wald R, Gore J, Wong GC, Gallo R, Welsh RC, Grondin FR, Kornder JM, De Young P, Bagnall AJ, Rose B, Fox KAA, Yan AT, on behalf of ACS Registries & GRACE Investigators. Temporal patterns in the management of non-ST elevation acute coronary syndromes in patients with renal dysfunction and associated outcomes. Can J Cardiol 2008;24(Suppl E):259E.

66. LaBounty T, Gurm HS, Goodman SG, Montalescot G, Lopez-Sendon J, Quill A, Eagle KA. Predictors and implications of Q-waves in ST-elevation myocardial infarction: A contemporary perspective from the Global Registry of Acute Coronary Events. Circ 2007;116(Suppl. 2):II-526.

67. Tricoci P, Mahaffey KW, O’Grady KG, Pieper KS, Newby LK, Harrington RA, Goodman SG, Gulba DC, Col J, White HD, Aylward PE, French JK, Kleiman NS, Ferguson JJ, Califf RM. Troponin elevation after percutaneous coronary intervention predicts major cardiac adverse outcomes in patients with non ST segment elevation acute coronary syndromes: Results from The SYNERGY Trial. J Am Coll Cardiol 2007;49(Suppl B):22B.

68. Petrina M, Eagle KA, Lopez-Sendon J, Step PG, Fox KA, Stiles M, Quill A, Goodman SG, for the GRACE Investigators. The prognostic value of the 12-lead electrocardiogram (ECG) in patients presenting with acute coronary syndromes (ACS): Insights from the Global Registry of Acute Coronary Events (GRACE) ECG substudy. J Am Coll Cardiol 2007;49(Suppl A):187A.

69. Goodman SG, Mahaffey KW, Chiswell K, Cohen M, Kontos MC, Antman EM, Ferguson JJ, Califf RM, Becker R. Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST segment elevation acute coronary syndromes treated with unfractionated heparin. J Am Coll Cardiol 2007;49(Suppl A):186A.

70. Yan RT, Yan AT, Welsh RC, Wong GC, Kornder JM, Rose B, Goodman SG. Coronary angiography and revascularization are paradoxically directed towards lower risk non-ST elevation acute coronary syndrome patients: Contemporary insights from GRACE & GRACE 2 in Canada. Can J Cardiol 2007;23(Suppl. C):121C.

71. Yan AT, Yan RT, Welsh RC, Wong GC, Lornder JM, Rose B, Goodman SG. Validation of multinational, registry-derived GRACE risk score in a broad spectrum of acute coronary syndrome patients in Canada. Can J Cardiol 2007;23(Suppl. C):98C.

72. Devlin G, Swanson N, Silverstone A, Montalescot G, Eagle KA, Goodman SG, Huang W, Brieger D. Do treatment delays influence outcomes following presentation with non-ST elevation acute coronary syndrome? The GRACE Registry. Eur Heart J 2007;28(Suppl. 1):65.

73. Gore J, Fox KA, Eagle KA, Furman M, Van De Werf F, Montalescot G, Goodman SG, Avezum A, Huang W, Steg PG. Increased all-cause mortality at 2 year follow-up after PCI with drug-eluting stents vs bare metal stents in acute coronary syndromes: The Global Registry of Acute Coronary Events experience. Presented at ‘Hotline & Clinical Trial Update’ session at the European Society of Cardiology Annual Congress 2007, Vienna.

74. Wang T, Goodman SG, Flather MD, Gurfinkel EP, Quill AL, Menon V. No impact of drug-eluting stents on rates of in-hospital coronary artery bypass surgery following non-ST-segment elevation myocardial infarction. The GRACE registry. Eur Heart J 2007;28(Suppl. 1):735.

75. McDonald MA, Fu Y, Zeymer U, Wagner GS, Goodman SG, Ross AM, Granger CB, Van de Werf F, Armstrong PW. Adverse outcomes in fibrinolytic-based facilitated PCI: Insights from the ASSENT-4 PCI electrocardiographic substudy. a) Can J Cardiol 2007;23(Suppl C):223C b) Eur Heart J 2007;28(Suppl 1):59

76. Bainey KR, Fu Y, Wagner G, Goodman SG, Ross A, Granger CB, Van de Werf F, Armstrong PW. Early ST resolution in STEMI: Spontaneous reperfusion in acute myocardial infarction. Can J Cardiol 2006;22(Suppl D):165D.

77. Fu Y, Goodman SG, Wagner G, Granger CB, Van de Werf F, Ross A, Armstrong PW. Q-waves at presentation relate to presentation delay and predict reperfusion likelihood and subsequent mortality. Can J Cardiol 2006;22(Suppl D):166D.

78. Yan RT, Yan AT, Allegrone J, Kennelly B, Budaj A, Georgescu A, Hassan Q, Goodman SG. ST-segment depression in non-ST elevation acute coronary syndromes: Quantitative analysis does not provide incremental prognostic value beyond comprehensive risk stratification. Can J Cardiol 2006;22(Suppl D):190D.

79. Jolly S, Goodman SG, Shenkman H, Brieger D, Fox KA, Yan AT, Anderson FA, Allegrone J, Eagle KA. Quantitative troponin predicts cardiogenic shock, sustained ventricular arrhythmias, cardiac arrest and reinfarction in non-ST elevation acute coronary syndromes. The GRACE Registry. a) Can J Cardiol 2006;22(Suppl D):166D b) Eur Heart J 2006;27(Suppl):1447

80. Yan RT, Yan AT, Allegrone, Lopez-Sendon J, Granger C, Gore J, Budaj A, Georgescu A, Hassan Q, Goodman SG. Failure to identify ST-segment deviation or left bundle branch block on the presenting electrocardiograms in patients with acute coronary syndromes is related to more adverse clinical outcome. Can J Cardiol 2006;22(Suppl D):194D.

81. Yan AT, Yan RT, Allegrone J, Kennelly B, Anderson F, Steg PG, Goodman SG. Prevalence and prognostic significance of ST elevation in aVR in patients with non-ST elevation acute coronary syndromes.
a) Eur Heart J 2005;26:282
b) Can J Cardiol 2006;22(Suppl D):193D

82. Lopez-Sendon JL, Goodman SG, Steg PG, Brieger D, Eagle K, Granger C, Gurfinkel E, Dedrick R, Gore JM, for the GRACE Investigators. Heparin therapy during fibrinolysis in ST-segment elevation myocardial infarction: Registry data support clinical trial results. Circ 2006;114(Suppl):II-863.

83. Linefsky JP, Mahaffey KW, Pieper KS, Lin A, Reist CJ, Antman EM, Goodman SG, French JK, Roe MT, Harrington RA, Ferguson JJ, Califf RM. Differences between site-reported and core laboratory creatine kinase-MB values in an international clinical trial: Results from the SYNERGY Trial. Circ 2006;114 (Suppl):II-417.

84. Nguyen M, Lim YL, Walton A, Lefkovits J, Agnelli G, Goodman SG, Budaj A, Gulba DC, Allegrone J, Brieger D, for the GRACE Investigators. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: Is it safe and effective use just one antiplatelet agent? J Am Coll Cardiol 2006;47(Suppl. A):252A.

85. Shishebor M, Lincoff AM, Yang H, Mahaffey KW, Becker RC, Goodman SG, Lansky A, Marian AJ, Stone G, Kleiman NS, Ferguson JJ, Califf RM, Topol E, Hazen SL. Plasminogen activator inhibitor-1 activity predicts clinical outcome in patients presenting with non-ST-segment elevation acute coronary syndromes: A SYNERGY Library analysis. Circ 2005;112(Suppl):II-140.

86. Shishehbor M, Lincoff AM, Lansky A, Mahaffey KW, Stone G, Yang H, Marian AJ, Ferguson JJ, Califf RM, Goodman SG, Kleiman NS, Topol E, Hazen SL, Becker RC. Lipid peroxidation products independently predict mortality in patients presenting with non-ST segment elevation acute coronary syndromes: A SYNERGY library analysis. Circ 2005;112(Suppl):II-388.

87. Eagle KA, Mehta RH, Nallamothu BK, Granger CB, Steg PG, Van de Werf F, Lopez-Sendon J, Goodman SG, Allegrone J, Fox KA, for the GRACE Investigators. Global reperfusion therapy in acute myocardial infarction – 1999 to 2004: We’re getting better, but we have a long way to go. The Global Registry of Acute Coronary Events. Circ 2005;112(Suppl):II-794.

88. Westerhout CM, Chang WC, Fu Y, Goodman SG, Van de Werf F, Granger CB, Armstrong PW. Are STEMI outcomes after fibrinolysis worse during “off hours”? Insights on circadian rhythm from ASSENT-2.
a) Circ 2005;112(Suppl):II-320
b) Can J Cardiol 2005;21(Suppl C):90C

89. Toma M, Fu Y, Wagner G, Goodman SG, Van de Werf F, Granger CB, Wallentin L, Armstrong PW, for the ASSENT 3 Investigators. Risk stratification in STEMI is enhanced by suing both baseline ST deviation and ST resolution at 180 mins. Can J Cardiol 2005;21(Suppl C):163C.

90. Toma M, Fu Y, Wagner G, Goodman SG, Van de Werf F, Granger CB, Wallentin L, Armstrong PW, for the ASSENT-3 Investigators. Enriching the prognostic value of the baseline ECG in STEMI. Can J Cardiol 2005;21(Suppl C):247C.

91. Spencer FA, Gore JM, Oliveira G, Montalescot G, Fox KAA, Goodman SG, Malone S, Granger CB, on behalf of the GRACE Investigators. Determinants of delay in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. The Global Registry of Acute Coronary Events. Eur Heart J 2005;26(Suppl):621.

92. Yan AT, Goodman SG, Kennelly BM, Anderson FA, Allegrone J, Steg PG, on behalf of the GRACE Investigators. Prevalence and prognostic significance of ST elevation in AVR: Insights from the Global Registry of Acute Coronary Events Electrocardiographic Substudy. Eur Heart J 2005;26(Suppl):282.

93. Fox KA, Anderson FA, Goodman SG, Dabbous OH, Gore JM, on behalf of the GRACE Investigators. Time course of events following presentation with acute coronary syndrome: Observations from 33,402 patients in the Global Registry of Acute Coronary Events. Eur Heart J 2005;26(Suppl):118.

94. Alghamdi S, Fu Y, Goodman SG, Change W-C, Van de Werf F, Granger CB, Armstrong PW. The baseline ECG in ST elevation myocardial infarction provides powerful prognostic insight: Observations from ASSENT-2. J Am Coll Cardiol 2005;45(Suppl A):208A.

95. Taher T, Al-Kurtass S, Fu Y, Wagner G, Goodman SG, Welsh R, Granger C, Wallentin L, Van de Werf F, Armstrong PW. The ECG adds value to time to treatment in predicting aborted myocardial infarction. J Am Coll Cardiol 2005;45(Suppl A):194A.

96. Ferguson JJ, Mahaffey KW, Huang Y, Armstrong PW, Levine G, Kleiman NS, Goodman SG, Cohen M, Antman E, Califf RM. Enoxaparin versus unfractionated heparin: Consequences of treatment duration on efficacy and safety in SYNERGY. J Am Coll Cardiol 2005;45(Suppl A):247.

97. Goodman SG, Yan AT, Allegrone J, Lopez-Sendon J, Granger CB, Gore JM, Budaj A, Georgescu AA, Hassan Q, Luchansky J, Van de Werf F, for the GRACE ECG Substudy Investigators. Disagreement in the interpretation of the admission electrocardiogram in acute coronary syndromes and association with clinical outcome: Real-world insights from GRACE. J Am Coll Cardiol 2005;45(Suppl A):240A.

98. Mahaffey KW, Levine G, Gallo R, Ducas J, Goodman SG, Lokhnygina Y, Traylor L, Antman E, White HD, Becker RC, Col JJ, Cohen M, Harrington RA, Ferguson JJ, Califf RM. Relationships between renal function, age, and obesity and outcomes in high-risk patients with acute coronary syndromes: Results from SYNERGY. J Am Coll Cardiol 2005;45(Suppl A):214A.

99. Singh KP, Roe MT, Peterson ED, Chen AY, Mhaffey KW, Goodman SG, Harrington RA, Ohman EM, Gibler B, Pollack CV. The safety of antithrombin therapy in non-ST-segment elevation acute coronary syndrome patients. Results from the CRUSADE initiative. J Am Coll Cardiol 2005;45(Suppl A):233A.

100. Rao SV, Mahaffey KW, Antman E, Kleiman NS, Ferguson JJ, Califf RM, Becker RC, Goodman SG, Aylward PE. Predictors of major bleeding and transfusion in SYNERGY: Effects of pre-treatment variables and treatment assignment. J Am Coll Cardiol 2005;45(Suppl A):247A.

101. Steg PG, Lopez-Sendon J, Lopez de Sa E, Goodman SG, Gore JM, Anderson FA Jr, Himbert D, Allegrone J, Van de Werf F, for the GRACE Investigators. Comparison of patients with ST-segment elevation myocardial infarction enrolled in fibrinolytic drug trials with trial-eligible and trial-ineligible patients. Findings from the Global Registry of Acute Coronary Events. Circ 2004;110(Suppl. III):III-783.

102. de Villiers JF, Fu Y, Wagner G, Goodman SG, Granger C, Wallentin L, Van de Werf F, Armstrong PW, for the ASSENT 3 Investigators. The acuteness score: New insights in predicting infarct size. J Am Coll Cardiol 2004;43(5;Suppl A):288A.

103. Alexander J, Yan H, Becker RC, Kodama K, Dyke CK, Goodman SG, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff M, Bovill EG, Kawai C, Armstrong PW, Harrington RA. Direct, selective factor Xa inhibition in patients with non-ST elevation acute coronary syndromes from the United States, Canada, and Japan: Results of the XaNADU-ACS trial. J Am Coll Cardiol 2004;43(5;Suppl A):302A.

104. Al-Kurtass S, Fu Y, Wagner G, Goodman S, Granger CB, Wallentin L, Van de Werf F, Armstrong PW. Does the baseline ECG add value to time to treatment in predicting successful reperfusion after fibrinolysis? Insight from ASSENT-3 and ASSENT 3+. Can J Cardiol 2004;20(Suppl D):108D.

105. Jelinek M, Goodman SG, Lopez-Sendon J, Gurfinkel E, White K, Brieger D. The impact of the new definition of acute myocardial infarction on patients discharged with unstable angina pectoris – six month outcomes: The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24(Suppl):723.

106. Johanson P, Fu Y, Dellborg M, Goodman SG, Armstrong PW, Krucoff MW, Wallentin L, Wagner GS. The model for a continuously updated weather-forecast before, during and after reperfusion therapy for estimations of final myocardial salvage: An ASSENT-2 electrocardiogram/VCG substudy. Eur Heart J 2003;24(Abstract Suppl):722.

107. Eagle KA, Lim MJ, Budaj A, Dabbous OH, Pieper K, Goodman SG, Granger CB, Steg PG, Gore JM, Fox KA. A robust prediction model for all forms of acute coronary syndromes: Estimating the risk of in-hospital death and myocardial infarction in the Global Registry of Acute Coronary Events (GRACE). J Am Coll Cardiol 2003;41(Suppl):353A.

108. Fox KAA, Anderson F, Goodman SG, Budaj A, Granger C, Flather M, Spencer F, Moscucci M, Dabbous O, Gore JM. Influence of guidelines and results from major clinical trials on medical practice: Findings from the Global Registry of Acute Coronary Events (GRACE). J Am Coll Cardiol 2003;41(Suppl A):518A.

109. Taher T, Fu Y, Wagner G, Goodman SG, Fresco C, Granger CB, Wallentin L, Van de Werf F, Armstrong PW, for the ASSENT 3 Investigators. Evidence for early reperfusion and preservation of myocardium: A new salvage subset. J Am Coll Cardiol 2003;41(Suppl A):358A.

110. Goodman SG, Granger CB, White K, Brieger D, Budaj A, Dabbous OH, Steg PG, on behalf of the GRACE Investigators. Acute coronary syndrome patients with ST-segment depression have substantial mortality rates but undergo less aggressive management strategies: Insights from the Global Registry of Acute Coronary Events (GRACE). J Am Coll Cardiol 2003;41(Suppl A):325A.

111. Armstrong PW, Wagner GS, Goodman S, Van de Werf F, Granger CB, Fu Y. Impact of fibrinolytic regimens and elapsed time on resolution of ST elevation in acute MI: Insights from the ASSENT 3 ECG substudy. J Am Coll Cardiol 2002;39(Suppl B):95B.

112. Taher T, Fu Y, Wagner G, Goodman S, Fresco C, Granger CB, Wallentin L, Van der Werf F, Armstrong PW, for the ASSENT 3 Investigators. Evidence for early reperfusion and preservation of myocardium: The ECG characteristics of aborted MI. Can J Cardiol 2002;18(Suppl. B):241B.

113. Leung R, Fu Y, Goodman SG, Wagner G, Granger CD, Wallentin L, Van de Werf F, Armstrong PW, for the ASSENT 3 Investigators. Does open-label reperfusion therapy in ST elevation acute myocardial infarction influence the frequency of urgent percutaneous coronary intervention: Can J Cardiol 2002;18(Suppl. B):140B.

114. Fox KAA, Goldberg RJ, Pieper K, Cannon CP, Van de Werf F, Goodman SG, Dabbous O, Granger CB, on behalf of the GRACE Investigators. Predictors of in-hospital mortality in the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002;23(Suppl):626.

115. Steg PHG, Feldman LJ, Brami M, Vahanian A, Eagle KA, Lopez-Sendon J, Dabbous O, Goodman SG, on behalf of the GRACE Investigators. Recurrent ischaemia in acute coronary syndromes: Differential impact of electrocardiographic changes on outcomes. Eur Heart J 2002;23(Suppl):588.

116. Brieger D, Eagle KA, Goodman SG, Lopez-Sendon J, Steg PHG, Budaj A, White K, Montalescot G, on behalf of the GRACE Investigators. Atypical presentation of acute coronary syndromes independently predicts myocardial infarction and increased in-hospital mortality: Insights from the GRACE Registry. Eur Heart J 2002:23(Suppl):105.

117. Wagner G, Fu Y, Goodman SG, Granger CB, Wallentin L, Van de Werf F, Armstrong P, on behalf of the ASSENT 3 Investigators. How does ST-segment resolution one-hour after fibrinolysis for acute myocardial infarction predict final infarct size? Insights from ASSENT 3. Eur Heart J 2002;23(Suppl): 266.

118. Furman MI, Davidson MC, Anderson FA, Jr, Budaj A, Goodman SG, Avezum A, Lopez-Sendon J, Klein W, Gore JM. Relationship between elevated leukocyte count and hospital clinical events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events. Circ 2001;104:II-650.

119. Van de Werf F, Avezum A, Gulba D, Goodman S, Budaj A, Brieger D, Gore J, Cannon C, White K, Kennelly B. Interventional procedures and in-hospital outcomes in patients with acute coronary syndromes: Observations from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2001;22(Suppl):617.

120. Gurfinkel EP, Duronto E, Lopez de Sa E, Avezum A, Sadiz I, Klein W, Goldberg RJ, Johnson J, Goodman SG. “Necrosette” infarction versus traditionally defined non-ST-segment elevation myocardial infarction (NSTEMI) and in-hospital course. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2001;22(Suppl):519.

121. Fu Y, Goodman S, Van de Werf F, Granger C, Armstrong P. The nature and outcome of patients who avoid myocardial necrosis after fibrinolysis. Eur Heart J 2001;22(Suppl):179.

122. Lockwood E, Fu Y, Wong B, Goodman S, Van de Werf F, Granger C, Armstrong PW, for the ASSENT-2 Investigators. Does 24-hour ST segment resolution post-fibrinolysis add prognostic value to a Q-wave? ASSENT-2 electrocardiographic substudy. Can J Cardiol 2001;17(Suppl C):182C.

123. Goodman S, Johnson J, Sullivan C, Steg PHG, Eagle K, Fox KAA, Lopez-Sendon J, Montalescot G, Budaj A, Kennelly B, Gore J, for the GRACE Investigators. What is an MI? Prospective analysis of the diagnostic and prognostic impact of adding troponins to the definition of myocardial infarction. J Am Coll Cardiol 2001;37(Suppl. A):358A.

124. Fu Y, Goodman S, Chang W-C, Kaul P, Van de Werf F, Granger CB, Armstrong PW, for the ASSENT 2 Investigators. Time to treatment influences the impact of ST segment resolution on one year prognosis: Insights from ASSENT-2. J Am Coll Cardiol 2001;37(Suppl A):340A.

125. Fu Y, Goodman S, Chang W-C, Barr A, Lagos M, Jagasia P, Van de Werf F, Granger C, Armstrong PW, for the ASSENT II Investigators. Incidence and prognosis of non-Q wave MI in the thrombolytic era: insights from ASSENT II. J Am Coll Cardiol 2000;35(suppl.A):390A.

126. Fu Y, Goodman S, Chang W-C, Kaul P, Van de Werf F, Granger CB, Armstrong PW, for the ASSENT 2 Investigators. Time to treatment influences the impact of ST segment resolution on one year prognosis: insights from ASSENT-2. J Am Coll Cardiol 2001;37(suppl A):340A.

127. Goodman S, Johnson J, Sullivan C, Stegg Ph G, Eagle K, Fox KAA, Lopez-Sendon J, Montalescot G, Budaj A, Kennelly B, Gore J, for the GRACE Investigators. What is an MI? Prospective analysis of the diagnostic and prognostic impact of adding troponins to the definition of myocardial infarction. J Am Coll Cardiol 2001;37(suppl A):358A.

128. Fu Y, Goodman S, Van de Werf F, Granger C, Armstrong P. The nature and outcome of patients who avoid myocardial necrosis after fibrinolysis. Eur Heart J 2001;22(Suppl):179.

129. Van de Werf F, Avezum A, Gulba D, Goodman S, Budaj A, Brieger D, Gore J, Cannon C, White K, Kennelly B. Interventional procedures and in-hospital outcomes in patients with acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2001;22(Suppl):617.

130. Gurfinkel EP, Duronto E, Lopez de Sa E, Avezum A, Sadiz I, Klein W, Goldberg RJ, Johnson J, Goodman SG. ‘Necrosette’ infarction versus traditionally defined non-ST-segment elevation myocardial infarction (NSTEMI) and in-hospital course. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2001;22(Suppl):519.

131. Lockwood E, Fu Y, Wong B, Goodman S, Van de Werf F, Granger C, Armstrong PW, for the ASSENT-2 Investigators. Does 24-hour ST segment resolution post-fibrinolysis add prognostic value to a Q-wave? ASSENT-2 electrocardiographic sub-study. Can J Cardiol 2001;17(suppl C):182-183C.

132. Goodman S, Bigonzi F, Radley D, Le louer V, Gosset F, Cohen M, for the ESSENCE Group. One year follow-up of the ESSENCE Trial (Enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction).
a) Eur Heart J 1998;19:50
b) J Am Coll Cardiol 1998;31(Suppl A):79A

133. Sgarbossa EB, Pinskey SL, Pavlovic-Surjancev B, Barbagelata A, Goodman SG, Underwood DA, Lum AS, Palvas B, Allen JE, Starr S, Paredes A, Wagner GS. A new hierarchy for ECG stratification of acute myocardial infarction based in T wave polarity. Circ 1998;98(Suppl I):I-555.

134. Cohen M, Weatherley B, Lee KL, Gurfinkel EP, Fromell G, Goodman S, Fox KAA. Multivariable analysis of predictors of recurrent ischemic events and death in unstable angina and non-Q wave infarction after treatment with combination antithrombotic therapy: Results from the ESSENCE trial. Circ 1997; 96(Suppl):I-596.

135. Pinski SL, Steinberg JS, Goodman SG, Helguera ME, Connors S, Song Q, Lawson WT, Gates K, Wagner GS. Lack of agreement in QT dispersion measurement by 3 different methods. PACE 1996;19(4, Part II):667.

136. Sgarbossa EB, Pinskey SL, Underwood DA, Stein S, Gates KB, Goodman S, Wagner GS. Post-thrombolysis reversion of bundle branch block in acute myocardial infarction is associated with improved prognosis. Electrocardiology 1996;29:545.